WO2004080973A1 - Inhibiteurs de pyrazole kinase fusionnee tricyclique et tetracyclique - Google Patents

Inhibiteurs de pyrazole kinase fusionnee tricyclique et tetracyclique Download PDF

Info

Publication number
WO2004080973A1
WO2004080973A1 PCT/US2004/006921 US2004006921W WO2004080973A1 WO 2004080973 A1 WO2004080973 A1 WO 2004080973A1 US 2004006921 W US2004006921 W US 2004006921W WO 2004080973 A1 WO2004080973 A1 WO 2004080973A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroindeno
pyrazol
methoxy
hydroxy
group
Prior art date
Application number
PCT/US2004/006921
Other languages
English (en)
Inventor
Yunsong Tong
Akiyo K. Claiborne
Gaoquan Li
Nan-Horng Lin
Hing Sham
Zhi-Fu Tao
Tom Sowin
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/792,564 external-priority patent/US7320986B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to EP04717503A priority Critical patent/EP1603885A1/fr
Priority to MXPA05009576A priority patent/MXPA05009576A/es
Priority to JP2006509216A priority patent/JP2006520400A/ja
Priority to CA002517885A priority patent/CA2517885A1/fr
Publication of WO2004080973A1 publication Critical patent/WO2004080973A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to fused pyrazoles, to methods of making the compounds, to compositions containing the compounds, and to methods of treatment using the compounds.
  • Protein kinases are important in the progression of many disease states that are induced by the inappropriate proliferation of cells. These kinases are often found to be up-regulated in many hyperproliferative states such as cancer. These kinases may also be important in cell signaling, where their inappropriate activation induces cells to proliferate (e.g., EGFR, ERBB2, VEGFR, FGFR, PDGFR, c-Met, IGF-lR, RET, TBE2). Alternatively, kinases may be involved in signal transduction within cells (e.g., c-Src, PKC, Akt, PKA, c-Abl, PDK-1) where these signal transduction genes are recognized proto-oncogenes.
  • kinases control cell cycle progression near the Gl-S transition (e.g., Cdk2, Cdk4), at the G2-M transition (e.g., Weel, Mytl, Chkl, Cdc2) or at the spindle checkpoint (Plk, Auroral or 2, Bubl or 3).
  • kinases are intimately linked to the DNA damage response (e.g., ATM, ATR, Chkl, Chk2).
  • Deregulation of these cellular functions: cell signaling, signal transduction, cell cycle control, and DNA repair are all hallmarks of hyperproliferative diseases, particularly cancer. Therefore, pharmacological modulation of one or more kinases would be useful in slowing or stopping diseases that are induced by the inappropriate proliferation of cells such as cancer.
  • the present invention relates to compounds of formula (I)
  • R ⁇ and R 2 are independently selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkynyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkyloxy, formyl, haloalkoxy, haloalkoxyalkynyl,
  • Ri and R 2 together with the carbon atoms to which they are attached form a 5, 6, 7, or 8- membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ), wherein the nonaromatic ring is substituted with 0, 1, or 2 substituents selected from the group consisting of alkyl and hydroxy;
  • R 3 is selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR E R F , (NR E Rp) lkoxy (NReR R lalkyl, (NR E RF)carbonyl, and (NR E RF)carbonylalkyl;
  • R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkylcarbonylalkoxy, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocycleoxy, hydroxy, -NR E R F , and (NR E R F )carbonyl;
  • R 5 is absent or selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, halogen, heteroaryl, hydroxy, nitro, -NR E R F , and (NR E Rp)carbonyl; or
  • R 4 and R 5 together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G RH, (NR ⁇ Ri alkoxy, (NR ⁇ R ⁇ alkyl, (NR ⁇ Ri ⁇ carbonyl, and (NR G R H )sulfonyl; or
  • R 4 and R 5 together with the atoms to which they are attached, form a heterocycle optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NR G RH, (NRGRH)alkoxy, (NRGR ⁇ -)alkyl, and (NR G RH)carbonyl; provided that when R 5 is hydrogen, R 4 is other than hydrogen;
  • R 6 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, halogen, hydroxy, and -NRERF;
  • R A and R B are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonylalkylalkylalky
  • Re and R D are independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, and alkylcarbonyl;
  • R E and R F are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl;
  • Xi, X 3 , and X are independently selected from the group consisting of CH and N;
  • X 5 is selected from the group consisting of C and N;
  • R 7 is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxy, lower alkoxy, lower alkyl, and hydroxyalkyl;
  • R 8 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, and hydroxyalkyl.
  • the present invention relates to pharmaceutical compositions comprising a compound of formula (I), or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.
  • the present invention relates to a method for inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.
  • the present invention relates to a method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.
  • Ri and R 2 are independently selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkynyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkyloxy, formyl, haloalkoxy, haloalkoxyalkynyl, haloalkyl, halogen, heteroarylalkoxy, heteroarylalkoxyalk
  • Ri and R 2 together with the carbon atoms to which they are attached form a 5, 6, 7, or 8- membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ), wherein the nonaromatic ring is substituted with 0, 1, or 2 substituents selected from the group consisting of alkyl and hydroxy;
  • R 3 is selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR E RF, (NRERp)alkoxy (NRERp) lkyl, (NR E Rp)carbonyl, and (NR E RF)carbonylalkyl;
  • R is selected from the group consisting of hydrogen, alkoxycarbonyl, alkylcarbonylalkoxy, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocycleoxy, hydroxy, -NR E R F , and (NRERp)carbonyl;
  • R 5 is absent or selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, halogen, heteroaryl,hydroxy, nitro, -NR E R F , an (NRERp)carbonyl; or
  • R 4 . and R 5 together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRQR H , (NR ⁇ Ri alkoxy, (NR G R ⁇ .)alkyl, (NR G R H )carbonyl, and (NR G R H )sulf
  • R and R 5 together with the atoms to which they are attached, form a heterocycle optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NR G RH, (NRoR ⁇ alkoxy, (NRoR ⁇ alkyl, and (NR G R H )carbonyl; provided that when R 5 is hydrogen, R 4 is other than hydrogen;
  • R 6 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, halogen, hydroxy, and -NRERF',
  • R A and R B are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonylalkylalkylalky
  • Re and R D are independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, and alkylcarbonyl;
  • R E and R F are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl;
  • X 1( X 3 , and X 4 are independently selected from the group consisting of CH and N;
  • X 5 is selected from the group consisting of C and N;
  • R 7 is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxy, lower alkoxy, lower alkyl, and hydroxyalkyl;
  • R 8 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, and hydroxyalkyl.
  • the present invention relates to a compound of formula (I) wherein X l5 X 3 , and X are CH; X is CH(R 7 ); X 5 is C; Rj and R 2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, heterocyclealkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ ) lkyl, and (NR A R ⁇ )carbonyl; R 3 is hydrogen; R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, aryl, carboxy, cyano, heteroaryl, hydroxy, -NR E R F , and (NR E Rp)carbonyl; R 5 is selected from the group consisting of hydrogen and -NR E R F ; R ⁇ is hydrogen; R 7 is hydrogen; R A is selected from the group consisting of hydrogen and alkyl; R ⁇ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heteroarylal
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R ); X 5 is C; Ri and R 2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRAR ⁇ )alkyl, (NR A RB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 3 is hydrogen; R is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, heteroaryl, hydroxy, -NR E R F , (NR E Rp)carbonyl, and aryl, wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy
  • RS is selected from the group consisting of hydrogen and -NR E R F ;
  • R O is hydrogen;
  • R 7 is hydrogen;
  • R A is selected from the group consisting of hydrogen and alkyl;
  • R ⁇ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
  • R E is selected from the group consisting of hydrogen and alkyl; and
  • R F is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • the present invention relates to a compound of formula (I) wherein X ls X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R l5 R 3 , R 5 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A R B )c rbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, and (NRERp)carbo yl; R is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohex
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R ); X 5 is C; Ri, R 3 , R 5 , and R 6 are hydrogen; R 2 is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ", 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloal
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R ); X 5 is C; Ri, R 3 , R5, and R 6 are hydrogen; R is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A R B )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is heteroaryl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and R B is selected from the group consisting of hydrogen and alkyl.
  • the present invention relates to a compound of formula (I) wherein X 1 ⁇ X 3 , and X are CH; X 2 is CH(R ); X 5 is C; R 1; R 3 , R5, and R 6 are hydrogen; R is alkenyloxy; R is heteroaryl wherein the heteroaryl is tetraazolyl; and R 7 is hydrogen.
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; Ri, R 3 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A R ⁇ )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, carboxy, and cyano; R 5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NR E R F , and (NR E R F )carbo yl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R ls R 3 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ ) lkyl, (NR A R ⁇ )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, carboxy, and cyano; R 5 is -NR E R F ⁇ R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
  • the present invention relates to a compound of formula (I) wherein X 1; X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R , R 3 , R 5 , and R 6 are hydrogen; Rt is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRAR ⁇ )alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E R F , and (NRERF) arbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is
  • the present invention relates to a compound of formula (I) wherein X l5 X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R 2 , R 3 , R 5 , and R 6 are hydrogen; Ri is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A RB)carbo yl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ; 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl,
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R ); X 5 is C; R 2 , R 3 , and R 6 are hydrogen; R t is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 4 is selected from the group consisting of hydrogen, carboxy, and cyano; R 5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NR E R F , and (NRERp)carbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cyclo
  • the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X 2 is CH(R ); X 5 is C; Ri and R 2 are alkoxy; R 3 and R 6 are hydrogen; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, -NR E R F , and (NRERp)carbonyl; R 5 is selected from the group consisting of hydrogen and carboxy; R 7 is hydrogen; R E is selected from the group consisting of hydrogen and alkyl; and R F is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X is CH(R 7 ); X 5 is C; Ri and R 2 are alkoxy; R 3 , R 5 , and R 6 are hydrogen; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ', 7 is hydrogen; R E is selected from the group consisting of hydrogen and alkyl; and R F is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; Ri and R 2 are alkoxy; R 3 , R5, and R 6 are hydrogen; R 4 is heteroaryl; and R 7 is hydrogen.
  • the present invention relates to a compound of formula (I) wherein X 1; X 3 , and X are CH; X 2 is CH(R 7 ); X5 is C; R ⁇ and R 2 are alkoxy; R 3 , R5, and R 6 are hydrogen; R 4 is heteroaryl wherein the heteraryl is tetraazolyl; and R 7 is hydrogen.
  • the present invention relates to a compound of formula (I) wherein X 1; X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; Ri, R 2 , R 3 , R 5 , and Rg are hydrogen; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E R F , and (NRERp)carbonyl; and R 7 is selected from the group consisting of alkoxy and hydroxy.
  • the present invention relates to a compound of formula (I) wherein Xi is CH; X 2 is CH(R 7 ); X 3 is N; X 4 is CH; X 5 is C; Ri, R 3 , R 5 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRAR ⁇ )alkyl, (NRAR B )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E RF, and (NRER F )carbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cyclo
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; Ri and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R 3 , R 5 , and R 6 are hydrogen; R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E RF, and (NRERp)carbonyl; R 7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; R ⁇ is selected from
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; R and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ); R 3 , R 5 , and R 6 are hydrogen; R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E R F , and (NRERF)carbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; R B is selected
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X is CH(R 7 ); X 5 is C; Ri and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ); R 3 , R S , and R 6 are hydrogen; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and - NR G R H ; R7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X5 is C; Ri and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R 3 , R5, and R 6 are hydrogen; R is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ; R7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R ⁇ )alkynyl, and (NRAR B )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R is aryl wherein
  • the present invention relates to a compound of formula (I) wherein Xi and X are CH; X 2 is CH(R 7 ); X 3 is N; X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRAR ⁇ )alkynyl, and (NR A R ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; Ri is selected from the group consisting of
  • the present invention relates to a compound of formula (I) wherein Xi and X 3 are CH; X 2 is CH(R 7 ); X4 is N; X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R ⁇ )alkynyl, and (NR A R B )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R 4 is selected from the
  • the present invention relates to a compound of formula (I) wherein Xi and X 3 are CH; X 2 is CH(R 7 ); X 4 and X5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRAR ⁇ )alkynyl, and (NRAR ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R is selected from the group consisting of cyan
  • the present invention relates to a compound of formula (I) wherein Xi and X 4 are CH; X 2 is CH(R 7 ); X 3 and X 5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R ⁇ )alkynyl, and (NR A R ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R 4 is selected from the group consisting
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R B )alkynyl, and (NR A R ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R and R 5 ,
  • alkenyl as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
  • Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl (allyl), 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2- heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
  • alkenyloxy means an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkenyloxy include, but are not limited to, allyloxy, 2-butenyloxy and 3-butenyloxy.
  • alkoxy as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
  • alkoxy alkoxy means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of alkoxyalkoxy include, but are not limited to, 2-(methoxy)ethoxy, 2-(ethoxy)ethoxy, 2-(tert-butoxy)ethoxy, and 3-(methoxy)butoxy.
  • alkoxyalkoxyalkynyl as used herein, means an alkoxyalkoxy group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of alkoxyalkoxyalkynyl include, but are not limited to, 3-(2-iso ⁇ ropoxyethoxy) ⁇ rop- 1 -ynyl, 3-(2-methoxyethoxy)prop- 1-ynyl, and 4-(2-iso ⁇ ropoxyethoxy)but- 1 -ynyl.
  • alkoxyalkyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxyalkyl include, but are not limited to, mefhoxymethyl, ethoxymethyl, 2-ethoxyethyl, tert-butoxymethyl, and 2-methoxyethyl.
  • alkoxyalkylcarbonyl as used herein, means an alkoxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxyalkylcarbonyl include, but are not limited to, 3- methoxypropanoyl and 5-methoxypentanoyl.
  • alkoxycarbonyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
  • alkoxycarbonylalkyl as used herein, means an alkoxycarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • alkoxycarbonylalkyl include, but are not limited to, 3- methoxycarbonylpropyl, 4-ethoxycarbonylbutyl, and 2-tert-butoxycarbonylethyl.
  • alkoxycarbonylalkylcarbonyl means an alkoxycarbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonylalkylcarbonyl include, but are not limited to, 5-methoxy-5-oxopentanoyl, 5-ethoxy-5-oxopentanoyl, and 4-methoxy-4-oxobutanoyl.
  • alkoxysulfonyl as used herein, means an alkoxy group, as defined herein, appended appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxy sulfonyl.
  • alkoxysulfonylalkyl as used herein, means an alkoxysulfonyl group, as defined herein, appended appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxysulfonylalkyl include, but are not limited to, 3-(methoxysulfonyl)propyl, 3-(ethoxysulfonyl)propyl, and 2-(methoxysulfonyl)ethyl.
  • alkoxysulfonylalkylcarbonyl means an alkoxysulfonylalkyl group, as defined herein, appended appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxysulfonylalkylcarbonyl include, but are not limited to, 3-(methoxysulfonyl)propanoyl, 3-(ethoxysulfonyl)propanoyl, and 4-(methoxysulfonyl)butanoyl .
  • alkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
  • alkylcarbonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-l-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
  • alkylcarbonylalkoxy means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of alkylcarbonylalkoxy include, but are not limited to, acetyl, 2-oxopropoxy, 2-oxobutoxy, and 3-oxobutoxy, 4-oxopentyloxy.
  • alkylcarbonyloxy means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
  • alkylsulfinyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein.
  • Representative examples of alkylsulfinyl include, but are not limited to, methylsulfinyl and ethylsulfinyl.
  • alkylsulfonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
  • alkylthio as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio.
  • alkylthioalkyl as used herein, means an alkylthio group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkylthioalkyl include, but are not limited, methylthiomethyl and 2- (ethylthio)ethyl.
  • alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
  • Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2- propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
  • aryl as used herein, means a monocyclic-ring system or a bicyclic-fused ring system wherein one or more of the fused rings are aromatic.
  • Representative examples of aryl include, but are not limited to, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
  • the aryl groups of the present invention are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G R H , (NRcR ⁇ alkoxy, (NRcR ⁇ lkyl, (NR G R H )carbonyl, and (NRcR H )sulfonyl.
  • the aryl groups of the present invention may be optionally substituted with one heterocycle, as defined herein.
  • the heterocycle may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G R H , (NR G R H )alkoxy, (NR G R H )alkyl, (NR G R H )carbonyl, and (NR G R H )s
  • arylalkoxy as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-phenylpropoxy, and 5- phenylpentyloxy.
  • arylalkyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of arylalkyl include, but are not limited to, 4-carboxyphenylmefhyl, 2-(4-hydroxyphenyl)ethyl, and 3-(4-carboxyphenyl)propyl.
  • aryloxy as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of aryloxy include, but are not limited to, 4-carboxyphenoxy, 4-hydroxyphenoxy, and 3,4- dihy droxyphenoxy .
  • carboxyalkyl as used herein, means a carboxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2- carboxyethyl, and 3-carboxypropyl.
  • carboxyalkylcarbonyl means a carboxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of carboxyalkylcarbonyl include, but are not limited to, 4- carboxybutanoyl, 3-carboxypropanoyl, and 5-carboxypentanoyl.
  • cyano means a -CN group.
  • cycloalkyl as used herein, means a saturated cyclic hydrocarbon group containing from 3 to 8 carbons. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • the cycloalkyl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, -NR G R H , (NR G R H )alkoxy, (NR G R H )alkyl, and (NR G R H )carbonyl.
  • cycloalkenyl means a non-aromatic, partially unsaturated monocyclic, bicyclic, or tricyclic ring system having four to eight carbon atoms and zero heteroatoms.
  • Representative examples of cycloalkenyl groups include, but are not limited to, cyclohexenyl and cyclopentenyl.
  • cycloalkenylalkoxy means a cycloalkenyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • cycloalkylalkoxy means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of cycloalkylalkoxy include, but are not limited to, cyclopropylmethoxy, 2-cyclobutylethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-cyclohexylethoxy, 3-cyclohexylpropoxy, 4-cyclohexylbutoxy, 4-(4-aminocyclohexyl)butoxy, 4-(4-dimethylaminocyclohexyl)butoxy, 4-(4-hydroxycyclohexyl)butoxy, and 4-cycloheptylbutoxy .
  • cycloalkylalkyl means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2- cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 4-(4-aminocyclohexyl)butyl, 4-(4-dimethylaminocyclohexyl)butyl, 4-(4- hydroxycyclohexyl)butyl, and 4-cycloheptylbutyl.
  • cycloalkylalkylcarbonyl means a cycloalkylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of cycloalkylalkylcarbonyl include, but are not limited to, 4- cyclohexylbutanoyl, 3-cyclohexylpropanoyl, and 5-cyclohexylpentanoyl.
  • cycloalkylcarbonyl as used herein, means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of cycloalkylcarbonyl include, but are not limited to, cyclohexylcarbonyl and cyclopentylcarbonyl.
  • cycloalkyloxy means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of cycloalkyloxy include, but are not limited to, cyclohexyloxy and cyclopentyloxy.
  • cycloalkylcarbonylalkyl as used herein, means a cycloalkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of cycloalkylcarbonylalkyl include, but are not limited to, 4- cyclohexyl-4-oxobutyl and 3-cyclohexyl-3-oxopropyl.
  • cycloalkylcarbonylalkylcarbonyl as used herein, means a cycloalkylcarbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of cycloalkylcarbonylalkylcarbonyl include, but are not limited to, 4-cyclohexyl-4-oxobutanoyl and 3 -cyclohexyl-3 -oxopropanoyl .
  • halo or halogen as used herein, means -Cl, -Br, -I or -F.
  • haloalkoxy means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Additionally, the alkyl group may optionally be substituted with at least one halogen atom.
  • Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2- fluoroethoxy, trifluoromethoxy, pentafluoroethoxy,and 3-chloro-2-(hydroxymethyl)-2- methylpropoxy.
  • haloalkoxyalkynyl as used herein, means a haloalkoxy group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of haloalkoxyalkynyl include, but are not limited to, 3-(2,2,2-trifluoroethoxy)prop-l-ynyl and 3-(trifluoromethoxy)prop-l-ynyl.
  • haloalkyl as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
  • heteroaryl refers to an aromatic five- or six-membered ring wherein 1, 2, 3, or 4 heteroatoms are independently selected from N, O, or S.
  • the five membered rings have two double bonds and the six membered rings have three double bonds.
  • the heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom.
  • heteroaryl also includes bicyclic systems where a heteroaryl ring is fused to a phenyl group or an additional heteroaryl group.
  • heteroaryl include, but are not limited to, benzothienyl, benzoxadiazolyl, cinnolinyl, furopyridinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, tetraazolyl, thiadiazolyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, and triazinyl.
  • heteroaryl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G R H , (NRcR ⁇ alkoxy, (NRcRH)alkyl, (NR G R H )carbonyl, and (NR G RH)sulfonyl.
  • heteroarylalkoxy means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of heteroarylalkoxy include, but are not limited to, 5-hydroxy-2- pyridinylmethyl, 2-(5-hydroxy-2-pyridinyl)ethyl, and 5-hydroxy-2-pyrimidinylmethyl.
  • heteroarylalkoxyalkoxy means a heteroarylalkoxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • heteroarylalkyl as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heteroarylalkyl include, but are not limited to, 5-carboxy-2- pyridinylmethyl, 5-hydroxy-2-pyridinylmethyl, 2-(5-hydroxy-2-pyridinyl)ethyl, and 3-(5- hydroxy-2-pyridinyl)propyl.
  • heteroarylalkynyl as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • heteroarylalkynyl include, but are not limited to, pyridin-2- ylethynyl, pyridin-3-ylethynyl, 4-pyridin-2-ylbut-l-ynyl, and 4-pyrazin-2-ylpent-l -ynyl.
  • heteroaryloxy means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of heteroaryloxy include, but are not limited to, 5-carboxy-2-pyridinyloxy, 5-hydroxy-2- pyridinyloxy, and 5-hydroxy-2-pyrimidinyloxy.
  • heteroaryloxyalkyl as used herein, means a heteroaryloxy group, as defined herein, appended to the parent molecular moiety through an alkyl group.
  • Representative examples of heteroaryloxyalkyl include, but are not limited to, pyridinyl5-carboxy-2- pyridinyloxymethyl, 5-hydroxy-2-pyridinyloxymethyl, and 5-hydroxy-2-pyrimidinyloxy.
  • heterocycle refers to a three, four, five, six, seven or eight membered ring containing one, two, or three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
  • the three membered ring has zero double bonds.
  • the four and five membered rings have zero or one double bond.
  • the six membered ring has zero, one, or two double bonds.
  • the seven and eight membered rings have zero, one, two, or three double bonds.
  • the heterocycle groups of the present invention can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom.
  • heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, azocanyl, l,4-diazepan-2-yl, 1,4-dioxanyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl, and 1,1-dioxidothiomorpholinyl.
  • heterocycles of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NR G R H , (NR G R H ) alkoxy, (NR G RH) lkyl, and (NRcR H )carbonyl.
  • substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloal
  • the heterocycles of the present invention may be optionally substituted with one aryl group, as defined herein.
  • the aryl group may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGR H , (NR G R H )alkoxy, (NR G R H )alkyl, (NR G RH)carbonyl, and (NR G R H )
  • heterocyclealkoxy means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of heterocyclealkoxy include, but are not limited to, 4-morpholinylmethoxy, 2-(4-morpholinyl)ethoxy, 4-thiomorpholinylmethoxy, 2-(4-thiomorpholinyl)ethoxy, 1 -piperidinylmethoxy, 2-(l-piperidinyl)ethoxy, 4-hydroxy-l- piperidinylmethoxy , 2-(4-hydroxy- 1 -piperidinyl)ethoxy, 3-hydroxy- 1 -pyrrolidinylmethoxy, 3-hydroxy- 1-azetidinylmethoxy, and 4-hydroxy-l-azepanylmethoxy.
  • heterocyclealkyl means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heterocyclealkyl include, but are not limited to, 4-morpholinylmethyl, 2-(4-morpholinyl)ethyl, 4-thiomorpholinylmethyl, 2-(4-thiomorpholinyl)ethyl, 1-piperidinylmethyl, 2-(l-piperidinyl)ethyl, 4-hydroxy-l- piperidinylmethyl, 2-(4-hydroxy- l-piperidinyl)ethyl, 3-hydroxy- 1-pyrrolidinylmethyl, 3-hydroxy-l-azetidinylmethyl, 3-hydroxy-l-azepanylmethyl, and 4-hydroxy-l-azepanylmethyl.
  • heterocyclealkylcarbonyl means a heterocyclealkyl, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclealkylcarbonyl include, but are not limited to, 4-(l- piperidinyl)butanoyl, 3-(l-piperidinyl)propanoyl, 4-(4-morpholinyl)butanoyl, and 3-(4-morpholinyl)propanoyl.
  • heterocyclecarbonyl means a heterocycle, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclecarbonyl include, but are not limited to, 4-morpholinylcarbonyl, 4-thiomorpholinylcarbonyl, 1-piperidinylcarbonyl, (4-hydroxy-l- piperidinyl)carbonyl, and 3-hydroxy-l-pyrrolidinylcarbonyl.
  • heterocyclecarbonylalkyl as used herein, means a heterocyclecarbonyl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heterocyclecarbonylalkyl include, but are not limited to, 2- (4-morpholinyl)-2-oxoethyl, 3-(4-morpholinyl)-3-oxopropyl, and 2-(l-piperidinyl)-2-oxoethyl.
  • heterocyclecarbonylalkylcarbonyl means a heterocyclecarbonylalkyl, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclecarbonylalkylcarbonyl include, but are not limited to, 5-(4-morpholinyl)-5- oxopentanoyl, 4-(4-morpholinyl)-4-oxobutanoyl, and 5-(l-piperidinyl)-5-oxopentanoyl.
  • heterocycleoxy means a heterocycle group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of heterocycleoxy include, but are not limited to, 4-piperidinyloxy, 3-py ⁇ olidinyloxy, 3-azetidinyloxy, and tetrahydrofuran-3-yloxy.
  • hydroxy as used herein, means an -OH group.
  • hydroxyalkoxy means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of hydroxyalkoxy include, but are not limited to, 2-hydroxyethoxy, 3-hydroxypropoxy, 2,3-dihydroxypropoxy, 2,3-dihydroxypentoxy, and 3-hydroxy-2,2- dimethylpropoxy .
  • hydroxyalkyl as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 2,3-dihydroxypentyl, 2-ethyl-4- hydroxyheptyl, and 3-hydroxy-2,2-dimethylpropyl.
  • hydroxyalkynyl as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of hydroxyalkynyl include, but are not limited to, 4-hydroxy-4- methylpent-1-ynyl, 4-hydroxybut-l-ynyl, and 3-hydroxyprop-l-ynyl.
  • hydroxyalkylcarbonyl means a hydroxyalkyl group, as defined herein, is appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of hydroxyalkylcarbonyl include, but are not limited to, glycoloyl, 3- hydroxypropanoyl, and 4-hydroxybutanoyl.
  • hydroxysulfonyl as used herein, means a HOS(O) 2 - group.
  • hydroxysulfonylalkyl as used herein, means a hydroxysulfonyl group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of hydroxysulfonylalkyl include, but are not limited to, 4- sulfobutyl, 3-sulfopropyl, and 2-sulfoethyl.
  • hydroxysulfonylalkylcarbonyl as used herein, means a hydroxysulfonylalkyl group, as defined herein, is appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of hydroxysulfonylalkylcarbonyl include, but are not limited to, 4-sulfobutanoyl and 3-sulfopropanoyl.
  • lower alkoxy as used herein, is a subset of alkoxy as defined herein and means a lower alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom, as defined herein.
  • Representative examples of lower alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, and 2-propoxy.
  • lower alkyl as used herein, is a subset of alkyl as defined herein and means a straight or branched chain hydrocarbon group containing from 1 to 3 carbon atoms. Examples of lower alkyl are methyl, ethyl, n-propyl, and iso-propyl.
  • mercapto as used herein, means a -SH group.
  • mercaptoalkyl as used herein, means a mercapto group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of mercaptoalkyl include, but are not limited to, hydroxymethyl, 2- mercaptoethyl, 3-mercaptopropyl, and 4-mercaptobutyl.
  • nitro as used herein, means a -N0 2 group.
  • R A and R B are each independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, hetero
  • Representative examples of -NRAR B include, but are not limited to, amino, methylamino, dimethylamino, cyclohexylamino, (trans)-4-methylcyclohexylamino, (cis)-4-methylcyclohexylamino, (trans)-4-hydroxycyclohexylamino, and (cis)-4-hydroxycyclohexylamino.
  • (NRAR B )alkoxy means a -NR A R B group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of (NR A R ⁇ ) lko y include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, 2- (dimethylamino)ethoxy, cyclohexylaminomethoxy, (trans)-4-methylcyclohexylaminomethoxy, (cis)-4-methylcyclohexylaminomethoxy, (trans)-4-hydroxycyclohexylaminomethoxy, and (cis)-4-hydroxycyclohexylaminomethoxy.
  • (NRAR B ) alkyl as used herein, means a -NR A R B group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR A R ⁇ )alkyl include, but are not limited to aminomethyl, 2- aminoethyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, 2- (dimethylamino)ethyl, cyclohexylaminomethyl, (trans)-4-methylcyclohexyla ⁇ inomethyl, (cis)- 4-methylcyclohexylaminomethyl, (1 ⁇ ans)-4-hydroxycyclohexylaminomethyl, and (cis)-4-hydroxycyclohexylaminomethyl.
  • (NRAR B ) lkynyl as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of (NR A R ⁇ )alkynyl include, but are not limited to 3-aminoprop-l-ynyl, 3-(dimethylamino)prop-l-ynyl, and 4-aminopent-l-ynyl.
  • (NRAR B )carbonyl as used herein, means a -NR A R B group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR A R B )carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
  • (NRAR ⁇ )carbonylalkyr' as used herein, means a (NR A R ⁇ )carbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • (NR A R ⁇ )carbonylalkyl include, but are not limited to, aminocarbonylmethyl, (methylamino)carbonylmethyl, (dimethylamino)carbonylmethyl, and (ethylmethylamino)carbonylmethyl.
  • -NR E R F means two groups, R E and Rp, which are appended to the parent molecular moiety through a nitrogen atom.
  • R E and R F are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl.
  • Representative examples of -NR E R F include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
  • (NR ⁇ R F koxy) means a -NR E R F group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of (NRERp)alkoxy include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, and 2- (dimethylamino)ethoxy.
  • (NRERp)alkyl as used herein, means a -NR E R F group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NRERp)alkyl include, but are not limited to aminomethyl, 2- aminoethyl, 3-aminopropyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, and 2-(dimethylamino)ethyl.
  • (NR E Rp)alkylcarbonyl means a (NR E R ⁇ )alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR E Rp)alkylcarbonyl include, but are not limited to aminoacetyl, 3-aminopropanoyl, 3-dimethylaminopropanoyl, and 4-aminobutanoyl.
  • (NRERF)carbonyl means a -NR E R F group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NRERp)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
  • (NRERF)carbonylalkyl means a (NRERp)carbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR E R F )carbonylalkyl include, but are not limited to, 2- amino-2-oxoethyl, 3-amino-3-oxopropyl, and 4-amino-4-oxobutyl.
  • (NRERF)carbonylalkylcarbonyl means a (NRER F )carbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NRER F )carbonylalkylcarbonyl include, but are not limited to, 3-amino-3-oxopropanoyl and 4- amino-4-oxobutanoyl .
  • (NRERF)sulfonyl means a -NR E RF group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of (NR E Rp)sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
  • (NRERF)sulfonylalkyl means a (NR E Rp)sulfonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR £ R F )sulfonylalkyl include, but are not limited to, 2- (aminosulfonyl)ethyl, 2-(methylaminosulfonyl)ethyl, 3-(dimethylaminosulfonyl)propyl, and 4- (ethylmethylaminosulf onyl)butyl .
  • (NRERp)sulfonylalkylcarbonyl means a (NR E Rp)sulfonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR E R F )sulfonylalkylcarbonyl include, but are not limited to, 3-(aminosulfonyl)propanoyl, 4-(methylaminosulfonyl)butanoyl, 4-(dimethylaminosulfonyl)butanoyl, and 4-(ethylmethylaminosulfonyl)butanoyl.
  • -NR G RH means two groups, R G and R H , which are appended to the parent molecular moiety through a nitrogen atom.
  • RQ and R H are each independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • Representative examples of -NR G R H include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
  • (NR G RH)alkoxy means at least one -NRQR H group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of (NR ⁇ R ⁇ lkoxy include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, 2-(dimethylamino)ethoxy, and 2-(dimethylamino)-l-[(dimethylamino)methyl]ethoxy.
  • (NRGRH)alkyl means a -NR G R H group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR ⁇ R ⁇ lkyl include, but are not limited to aminomethyl, 2- aminoethyl, 3-aminopropyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, and 2-(dimethylamino)ethyl.
  • (NRGRH)carbonyl means a -NR G R H group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR G R H )carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
  • (NRGRH)sulfonyl means a -NR G R H group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of (NR G R ⁇ )sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
  • This invention is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes. Preparation of the compounds of the invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro.
  • the compounds of the present invention can exist as therapeutically acceptable salts.
  • therapeutically acceptable salt represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethansulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate,trifluoroacetate, phosphate, glutamate, bi
  • amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethyla ine, diethylamine, ethylamine, tributylamine, pyridine, N,N- dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procame, dibenzyl amine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N - dibenzylethylenediamine.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • the present compounds can also exist as therapeutically acceptable prodrugs.
  • therapeutically acceptable prodrug refers to those prodrugs which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • prodrug refers to compounds which are rapidly transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood.
  • a representative example of a prodrug of the present invention includes, but is not limited to, 4'-(6,7-dimethoxy-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-yl 1 ,4'-bipiperidine-l '-carboxylate.
  • Asymmetric centers exist in the compounds of the present invention. These centers are designated by the symbols "R” or "S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases.
  • Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns.
  • Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the ait.
  • the compounds can be administered alone or in combination with other anticancer agents.
  • the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used.
  • the compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof.
  • parenteral includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection.
  • Parenterally administered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents.
  • the injectable preparation can also be an injectable solution or suspension in a diluent or solvent.
  • acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides.
  • the anticancer effect of parenterally administered compounds can be prolonged by slowing their absorption.
  • One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound.
  • the rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state.
  • Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension.
  • injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or poly anhydrides.
  • biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or poly anhydrides.
  • the rate of drug release can be controlled.
  • Transdermal patches can also provide controlled delivery of the compounds.
  • the rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel.
  • absorption enhancers can be used to increase absorption.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound can optionally comprise diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose.
  • Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling coatings.
  • Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefore.
  • Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
  • Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches.
  • the compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers.
  • These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
  • the total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from about 0.25 to about 100 mg/kg body weight.
  • Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose.
  • the Chkl enzymatic assay was carried out using recombinant Chkl kinase domain protein covering amino acids from residue 1 to 289 and a polyhistidine tag at the C-terminal end.
  • Human cdc25c peptide substrate contained a sequence from amino acid residue 204 to 225.
  • the reaction mixture contained 25 mM of HEPES at pH 7.4, 10 mM MgCl 2 , 0.08 mM Triton X-100, 0.5 mM DTT, 5 ⁇ M ATP, 4 nM 33P ATP, 5 ⁇ M cdc25c peptide substrate, and 6.3 nM of the recombinant Chkl protein.
  • Compound vehicle DMSO was maintained at 2% in the final reaction.
  • Compounds of the present invention inhibited Chkl at IC 50 alues between about 0.1 nM and about 10,0000 nM.
  • Preferred compounds inhibited Chkl at IC 50 values between about 0.1 nM and about 250 nM.
  • Most preferred compounds inhibited Chkl at IC 50 values between about 0.1 nM and about 50 nM.
  • the compounds of the invention are useful in treating disorders which are caused or exacerbated by increased protein kinase levels.
  • the compounds of the invention possess the ability to inhibit protein kinases.
  • protein kinase inhibitors are useful in the treatment of both primary and metastatic solid tumors, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemaiigiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well
  • Such compounds may also be useful in treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungicides and cutaneous T- cell lymphoma/leukemia) as well as in the treatment of lymphomas (both Hodgkin's and non- Hodgkin's lymphomas).
  • leukemias i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungicides and cutaneous T- cell lymphoma/leukemia
  • lymphomas both Hodgkin's and non- Hodgkin's lymphomas.
  • these compounds may be useful in the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.
  • 3,6-Disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (5) and (6), wherein R A , R B , R , R 5 , and Rg are as defined in formula (I), can be prepared as described in Scheme 1.
  • l,4-Dihydroindeno[l,2-c]pyrazole-6-carbaldehyde prepared using the procedure described in US 6,297,238, herein incorporated by reference, can be treated with N- iodosuccinimide to provide 3-iodo-l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde.
  • 3-Iodo- l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde can be treated with amines of general formula (1) (or H 2 NOH) and a reducing agent, including but not limited to, sodium borohydride or sodium cyanoborohydride to provide amines of general formula (2).
  • a reducing agent including but not limited to, sodium borohydride or sodium cyanoborohydride
  • Amines of general formula (2) can be treated with boronic acids of general formula (4) (or 4,4,5,5-tetramethy-l,3,2- dioxaborolanes), a base, including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate, and a metal catalyst, including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (5).
  • boronic acids of general formula (4) or 4,4,5,5-tetramethy-l,3,2- dioxaborolanes
  • a base including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate
  • a metal catalyst including but not limited to, tetrakis(triphenylphoshine)palladium or bis(tri
  • 3-Iodo-l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde can also be treated with nitrogen containing heterocycles, including but not limited to, azetidine, azepane, aziridine, azocane, morpholine, mono-protected piperazine, piperidine, 4-hydroxypi ⁇ eridine, pyrrolidine, thiomorpholine, or 1,1-dioxidothiomorpholine, for example, to provide compounds of general formula (3).
  • nitrogen containing heterocycles including but not limited to, azetidine, azepane, aziridine, azocane, morpholine, mono-protected piperazine, piperidine, 4-hydroxypi ⁇ eridine, pyrrolidine, thiomorpholine, or 1,1-dioxidothiomorpholine, for example, to provide compounds of general formula (3).
  • Compounds of general formula (3) can be treated with boronic acids of general formula (4), a base, including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate, and a metal catalyst, including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (6).
  • a base including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate
  • a metal catalyst including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (6).
  • 3,7-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles can be prepared from l,4-dihydroindeno[l,2-c]pyrazole-7-carbaldehyde using the methodology described in Scheme 1.
  • 5,6-Dimethoxy-l- indanone purchased from Aldrich Chemical Co., can be treated with sodium cyanide to provide 5-hydroxy-6-methoxy-l-indanone.
  • 5-Hydroxy-6-methoxy-l-indanone can be treated with nitric acid and sodium nitrite to provide 5-hydroxy-6-methoxy-4-nitro-l-indanone.
  • 5-Hydroxy-6- methoxy-4-nitro-l-indanone can be treated with iodomethane and then methodology described in Scheme 2 to provide compounds of general formula (12).
  • Compounds of general formula (12) can be treated with a reducing agent, including iron metal in the presence of acetic acid, to provide amines of general formula (13).
  • Compounds of general formula (13) where R 4 is chlorine, bromine or iodine can be further elaborated under Heck, Suzuki, or Stille conditions to provide compounds of general formula (13) wherein R 4 is aryl or heteroaryl as defined herein.
  • An example of suitable Suzuki conditions is described in Example ID herein or Suzuki conditions as described in N. Miyaura, A. Suzuki, Chem.
  • Compounds of general formula (13), wherein R) is chlorine, bromine, or iodine can be treated with aryl or heteroaryl stannanes (Me 3 SnR , Bu 3 SnR 4 ), purchased or prepared using known mehodology, a palladium source such as tris(dibenzylidineacetone)dipalladium or palladium diacetate, and a ligand such as tri(2-furyl)phosphine or triphenyl arsine in a solvent such as DMF at 25-150 °C (Stille conditions) to provide compounds of general formula (13) wherein R 4 is aryl or heteroaryl as defined herein.
  • aryl or heteroaryl stannanes Me 3 SnR , Bu 3 SnR 4
  • a palladium source such as tris(dibenzylidineacetone)dipalladium or palladium diacetate
  • a ligand such as tri(2-furyl)phosphin
  • Organotin reagents can be prepared from arylhalides, aryltriflates, heteroarylhalides, or heteroaryltriflates by reaction with distannanes like (Me 3 Sn) 2 (hexamethyl distannane) in the presence of a palladium source like Pd(Ph 3 P) as described in Kharia, et. al., Helvetica Chimica Acta, 1909-1920:81(11) (1998) and in Benaglia, et al., Tetrahedron Letters, 4737-4740:38 (1997) 38.
  • distannanes like (Me 3 Sn) 2 (hexamethyl distannane)
  • Pd(Ph 3 P) palladium source
  • 2,3,7,8- Tetrahydro-6H-indeno[5,6-b][l,4]dioxin-6-ones of general formula (16) can be treated under conditions as described in Scheme 2 to provide 1,4,7,8- tetrahydro[l,4]dioxino[2',3':5,6]indeno[l,2-c]pyrazoles of general formula (17), including but not limited to, 4-(l,4,7,8-tetrahydro[l,4]dioxino[2',3':5,6]indeno[l,2-c]pyrazol-3-yl)-l,l - biphenyl-4-ol.
  • Example 1A 1 ,4-Dihydro-indeno ⁇ 1 ,2-c1pyrazole-6-carbaldehyde
  • 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (0.100 g, 0.425 mmol, see U.S. Patent 6297238 for preparation) in THF (3 mL) at -78 °C was added 1.8 M PhLi in cyclohexane/ether (0.71 mL, 1.28 mmol) followed by 1.3 M s-BuLi in cyclohexane (0.98 mL, 1.28 mmol) 30 minutes later.
  • the reaction mixture was stirred at -78 °C for 60 minutes and DMF (0.33 mL, 4.25 mmol) was added. The dry ice bath was removed after 30 minutes. After an additional 30 minutes, the reaction was quenched with water. The reaction mixture was extracted with EtOAc, washed with 50% brine, dried over MgSO , filtered, and concentrated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (7:3 to 8:2) to give 0.053 g (68%) of the desired product as brown solid..
  • Example IB 3-Iodo- 1.4-dihydro-indenof 1 ,2-clp yrazole-6-carbaldehyde
  • a suspension of Example 1A (7.90 g, 0.0429 mol) and N-iodosuccinimide (11.6 g, 0.0515 mol) in DMF (150 mL) was heated at 80 °C for 5.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was triturated with EtOAc and ether to give 7.20 g of brown solid as the desired product. The filtrate was concentrated and purified by flash cliromatography eluted with EtOAc/hexane (7:3) to give 1.30 g of the desired product (combined yield: 64%).
  • Example 1C N-
  • 4- methylcyclohexylamine hydrochloride (8.66 g, 0.0579 mol) and potassium carbonate (4.81 g, 0.0348 mol).
  • Example ID 4-(6- ⁇ T(1xans-4-methylcvclohexyl aminolmethyl ⁇ - 1.4-dihvdroindeno[ 1 ,2-clpyrazol-3-yl)benzoic acid A mixture of Example 1C (trans, 45.0 mg, 0.110 mmol), 4-carboxybenzene boronic acid (20.1 mg, 0.121 mmol), Na 2 C0 3 (1 M, 0.26 mL, 0.264 mmol), and Pd(PPh 3 ) 2 Cl 2 (7.70 mg, 0.0110 mmol) in DME/EtOH/H 2 O (7:2:3, 1.2 mL) in a capped 2 mL vial was heated at 160 °C for 450 seconds in a Smith Synthesizer (300 W).
  • the reaction was cooled using 40 psi pressurized air. Solvents were evaporated and the crude product was purified using preparative HPLC to give 25.0 mg (26%) of the desired product as pale yellow foam.
  • the purification was processed on a Waters Symmetry C8 column (25mm X 100mm, 7 ⁇ m particle size) using a gradient of 10% to 100% acetonitrile: 0.1% aqueous TFA over 8 min (lOmin run time) at a flow rate of 40 mL/min.
  • Example 2 4-(6- ⁇ r(cis-4-methylcvclohexyl)aminolmethyl I - 1 ,4-dihydroindeno
  • the desired product was prepared using the procudure in Example ID replacing the trans product from Example 1C with the cis product from Example lC.
  • Example 3 ethyl 4-(6-( F(trans-4-methylcyclohexyl)aminolmethyl i-1 ,4-dihydroindeno IT ,2-c1pyrazol-3- yPbenzoate
  • trans 45.0 mg, 0.110 mmol
  • DME/EtOH/H 2 0 7.3:2
  • 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzoic acid ethyl ester (31.8 ⁇ L, 0.121 mmol), Na 2 C0 3 (IM, 0.11 mL), and Pd(PPh 3 ) 2 Cl 2 (7.7 mg, 0.0110 mmol).
  • Example 4A frans-4-r(3-Iodo-l,4-dihydro-indenori,2-clpyrazol-6-ylmethyl)-aminol-cyclohexanol
  • the desired product was prepared by replacing 4-methylcyclohexylamine hydrochloride with trans-4-hydroxycyclohexylamine hydrochloride in Example IC.
  • Example 4B 4-(6- ⁇ r(trans-4-hydroxycvclohexyl)aminolmethyl ⁇ -l,4-dihydroindeno ⁇ ,2-clpyrazol-3- vDbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 4A in Example ID.
  • Example 5 N- 1 " 3-(6- ⁇ r(trans-4-hvdroxycvclohexyl)amino1mefhyl 1-1 ,4-dihydroindeno I " 1 ,2-c1pyrazol-3- vDphenyllacetamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and 3-acetamidobenzene boronic acid in Example ID.
  • Example 6 4-(6- ⁇ r(frans-4-hydroxycyclohexyl)aminolmethyli-1.4-dihvdroindenori,2-c1pyrazol-3- vPbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 7A 3-Iodo-6-morpholin-4-ylmethyl- 4-dihvdro-indenori,2-clpyrazole
  • a mixture of Example IB (1.00 g, 3.22 mmol), morpholine (0.84 mL, 9.66 mmol), and TsOH.H 2 O (61.2 mg, 0.322 mmol) in toluene (50 mL) was heated to refluxing overnight. The solvent was evaporated. To the resulting residue were added EtOH (40 mL), THF (10 mL), and NaBH (0.182 g, 4.83 mmol) at room temperature. The mixture was stirred overnight and the resulting solid was filtered. The filtrate was concentrated, treated with IN HC1, and extracted with EtOAc.
  • Example 7B 4-r6-(4-morpholinylmethyl -l,4-dihydroindenori,2-clpyrazoI-3-yllbenzoic acid
  • Example 8 methyl 4- r6-(4-morpholinylmethyl)- 1 ,4-dihydroindeno [1 ,2-clpyrazol-3-yl1benzoate
  • MeOH MeOH
  • HC1 0.50 mL
  • the reaction mixture was concentrated and purified using HPLC.
  • the TFA salt of the desired product was converted into the HC1 (17.0 mg, 81%) using the procedure in Example 7B.
  • the HPLC condition is indicated as the following: Dynamx C18 (5 ⁇ m, 21.4x250 mm) column was used containing a Rainin Dynamax solvent delivery system with a Dynamax UV-D II detector.
  • the solvent system used was a 20% to 100% acetonitrile/water containing 0.1% TFA linear gradient.
  • the elution rate was 10 mL/min and the UV detection wavelength was set at 254 nm).
  • Example 9 4-F6-(4-morpholinylmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yllbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • the product was purified by flash chromatography eluted with EtOAc/MeOH NH 4 OH (10:1:0.1).
  • Example 10 N-(3-r6-(4-morpholinylmethyl)-l,4-dihydroindenon,2-clpyrazol-3-vnphenyljacetamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and 3-acetamidobenzeneboronic acid in Example ID.
  • Example 11 A N-(5-Bromo-2-methyl-phenyl)-acetamide To a solution of 3-bromo-6-mefhylaniline (1.00 g , 5.37 mmol) in pyridine (8 mL) was added acetyl chloride (0.76 mL, 10.7 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour and concentrated. The residue was extracted with EtOAc, washed with 5% citric acid, dried over MgSO 4 , concentrated, and triturated with ether to give 0.750 g (61%) of the desired product as off-white crystal.
  • Example 11C 2-Acetylamino-4-(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-benzoic acid methyl ester
  • TMSCHN 2-Acetylamino-4-(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-benzoic acid methyl ester
  • Example IC The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and Example 1 IC in Example ID.
  • the product was purified using the HPLC condition in Example 8.
  • Example 12 4- f 6- r(4-h ydroxy- 1 -piperidinypmethyll- 1 ,4-dihydroindeno [ " 1 ,2-clpyrazol-3-yl Ibenzoic acid
  • Example 12A l-(3-Iodo-l,4-dihvdro-indeno ⁇ .2-clpyrazol-6-ylmethyl)-piperidin-4-ol
  • the desired product was prepared by replacing morpholine with 4-hydroxypiperidine in Example 7A.
  • Example 12B 4- ⁇ 6- r(4-hvdroxy- 1 -piperidinvDmethyll- 1 ,4-dihydroindeno I " 1 ,2-c1pyrazol-3-yl Ibenzoic acid
  • the desired product was prepared by replacing Example IC with Example 12A in Example ID.
  • Example 13 4- ( 6-r(4-hydroxy- 1 -piperidinvDmethyll- 1 ,4-dihydroindenor 1 ,2-c1pyrazol-3-yl Ibenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 12A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 14 N-(3 - ⁇ 6- r (4-hydroxy- 1 -piperidmvDmethyl] - 1 ,4-dihydroindeno [ " 1 ,2-clpyr azol-3- yl 1 phenyl) acetamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 12A and 3-acetamidobenzeneboronic acid in Example ID.
  • Example 15 A (2,2-Dimethyl-propyl)-(3-iodo-l,4-dihydro-indenori,2-c1pyrazol-6-ylmethyl)-amine
  • the desired product was prepared by replacing morpholine with neopentylamine in Example 7A.
  • MS (DC17NH 3 ) m/z: 382.1 (M+H) + ; 1H NMR (300 MHz, CD 3 OD) ⁇ 0.92 (s, 9H), 2.34 (s, 2 H), 3.53 (s, 2 H), 3.82 (s, 2 H), 7.35 (d, J 7.80 Hz, 1 H), 7.52-7.61 (m, 2 H).
  • Example 15B 4-16-f (neopentylamino)methyn- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-3-yl Ibenzoic acid
  • the desired product was prepared by replacing Example IC with Example 15 A in Example ID.
  • Example IC The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 15A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 17 A 3- F(3-Iodo- 1 ,4-dihydro-indenoF 1 ,2-clp yrazol-6-ylmethyl)-amino1-2,2-dimethyl-propan- 1 -ol
  • the desired product was prepared by replacing morpholine with 3-amino-2,2-dimefhyl-l- propanol in Example 7A.
  • Example 17B 4-(6- ( F(3-hydroxy-2,2-dimethylpropyl)amino1methyl 1-1 ,4-dihydroindeno F 1 ,2-clpyrazol-3- vDbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 17 A in Example ID.
  • Example 18 4-(6-( F(3-hydroxy-2,2-dimethylpropyl)aminolmethyl ⁇ -l,4-dihydroindenoFl,2-clpyrazol-3- ypbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 17A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 19A (3-Iodo-l,4-dihydro-indenoFl,2-clpyrazol-6-yl)-methanol
  • a suspension of Example IB (0.500 g, 1.61 mmol) in a mixture of MeOH (9 mL) and THF (3 mL) was added NaBH (73.0 mg, 1.93 mmol) at room temperature.
  • the mixture was stirred for 2 hours and the solvent was evaporated.
  • the resulting concentrate was dissolved in hot CH 2 CI 2 with a small amount of MeOH and the desired product was recrystalized to give 0.324 g (65%) of the desired product as brown solid.
  • Example 19B 4-F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-c1pyrazol-3-vnbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 19A in Example ID.
  • Example 20 4-F6-(hvdroxymethyl)-l,4-dihydroindenoFl,2-clpyrazol-3-yllbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 21 A 3-Iodo-6-methoxymethyl-l ,4-dihydro-indenoFl ,2-clpyrazole
  • a mixture of Example 19A (0.294 g, 0.942 mmol), LiBr (0.090 g, 1.04 mmol), and PBr 3 (0.14 mL, 11.49 mmol) in DMF (5 mL) was stirred at room temperature for 2 hours. Ice was added to the reaction mixture and the resulting precipitate was filtered. The solid was suspended in MeOH and treated with Et 3 N (1 mL). The mixture was concentrated and purified by flash chromatography eluted with EtOAc/CH 2 Cl 2 (2:98 to 5:95) to give 0.0422 g (12%) of the desired product.
  • Example 2 IB 4- F6-(methoxymethyl)- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-3-yllbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 21 A in Example ID.
  • Example 22A 5-Allyloxy-indan- 1 -one To a solution of 5 -hydroxy- 1-indanone (4.27 g, 0.0288 mol) in THF/DMF (5 mL/10 mL) at 0°C was added NaH (60%, 1.21 g, 0.0303 mol) followed by allyl bromide (2.7 mL, 0.0317 mol). The reaction was warmed to room temperature and stirred overnight. The reaction mixture was quenched with water and extracted with EtOAc, washed with brine, dried over MgSO , filtered, and concentrated. The residue was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 4.29 g (79%) of the desired product as brown oil.
  • Example 22B methyl 4-F(5-(allyloxy)-l-oxo-l,3-dihydro-2H-inden-2-ylidene)(hvdroxy)methyllbenzoate
  • LDA 2.0M, 0.65 mL, 1.30 mmol
  • a pre-mixed suspension of CDI 0.191 g, 1.18 mmol
  • terephthalic acid monomethyl ester 0.213 g, 1.18 mmol
  • Example 22C methyl 4-F6-(allyloxy)-l,4-dihydroindenoFl,2-c
  • a mixture of Example 22B (1.70 g, 4.85 mmol), hydrazine monohydrate (0.28 mL, 5.82 mmol), and AcOH (0.33 mL, 5.82 mmol) in EtOH (120 mL) was heated at 90 °C overnight. The reaction was cooled and the precipitate was filtered. The filter cake was rinsed with ether to give 1.56 g (93%) of the desired product as a white solid.
  • Example 22D 4-F6-(allyloxy)-l,4-dihydromdenoFl,2-clpyrazol-3-vHbenzoic acid
  • Example 23 4-F6-(allyloxy)-l,4-dihvdroindenoFl,2-clpyrazol-3-vnbenzamide
  • a mixture of Example 22D (50.0 mg, 0.150 mmol), HOBt (28.5 mg, 0.211 mmol), EDC (40.4 mg, 0.211 mmol), NH 4 C1 (40.1 mg, 0.750 mmol), and Et 3 N (0.14 mL, 0.975 mmol) in DMF (3 mL) in a capped flask was stirred at room temperature for 24 hours. The reaction mixture was diluted with EtOAc and washed with NaHCO 3 and brine.
  • Example 24 methyl 4-(6-hydroxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)benzoate
  • THF 16 mL
  • Pd(PPh 3 ) 4 0.0130 g, 2%
  • a suspension of NaBH in THF (2 mL) was added to the above reaction mixture in three portions at 0°C. The reaction was warmed to room temperature and stirred overnight. The reaction mixture was treated with acetone and the solvent was evaporated. The residue was treated with warm MeOH and the solid was filtered.
  • the desired product was prepared by replacing Example 22C with Example 24 in
  • Example 26A 3-Iodo- 1 ,4-dihydro-indeno F 1 ,2-clpyrazole-6-carboxylic acid
  • NaC10 2 (1.14 g, 0.0126 mol) in H 2 0 (15 mL) dropwise.
  • the reaction mixture was stirred for 15 minutes at 0 °C followed by the addition of NaHSO 3 (1.11 g, 0.0106 mol). The resulting suspension was warmed to room temperature and stirred for 1 hour. The reaction mixture was treated with Na 2 S 2 O3 solution and concentrated under reduced pressure. The residue was treated with water and stirred for 1 hour. The mixture was filtered and the filter cake was rinsed with water and dried in a vacuum oven to provide the title compound which was used in the next step without further purification.
  • Example 26B 3-Iodo-l,4-dihvdro-indenoFl,2-clpyrazole-6-carboxylic acid (4-hydroxy-cyclohexyl)-amide
  • the desired product was prepared by replacing NH 4 C1 and Example 22D with trans-4- amino-cyclohexanol and Example 26A in Example 23.
  • Example 26C 4-(6- ⁇ F(trans-4-hydroxycyclohexyl aminolcarbonyl)-l,4-dihydroindenori,2-clpyrazol-3- yDbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 26B in Example ID.
  • Example 27A 3-Iodo- 1 ,4-dihy dro-indenoF 1 ,2-c]pyrazole-6-carboxylic acid (2,2-dimethyl-propyP-amide
  • the desired product was prepared by replacing NH C1 and Example 22D with neopentylamine and Example 26A in Example 23.
  • Example 27B 4-(6-F(neopentylamino)carbonyll-l,4-dihvdroindenoFl,2-clpyrazol-3-yllbenzoic acid The desired product was prepared by replacing Example IC with Example 27 A in Example ID.
  • Example 28 3-F4-(ar nocarbonyl)phenyll-N-neopentyl-l,4-dihvdroindenoFl,2-clpyrazole-6-carboxamide
  • the desired product was prepared replacing Example IC and 4-carboxybenzene boronic acid with Example 27A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 29A 4'-(4,4,5,5-Tetramethyl-Fl,3,21dioxaborolan-2-vP-bi ⁇ henyl-4-ol
  • Example 29B 4-(6- ⁇ F(cis-4-methylcyclohexyPaminolmethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yP-l,r- biphenyl-4-ol
  • the desired product was prepared by replacing Example IC (trans) and 4-carboxybenzene boronic acid with Example IC (cis) and Example 29A in Example ID.
  • Example 30A 4 -Bromo-3 -methox y-biphenyl-4-ol
  • 2-methoxy-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol (0.250 g, 1.00 mmol)
  • 1,4-dibromo benzene 0.259 g, 1.10 mmol
  • Pd(PPh 3 ) 0.0580 g, 5%
  • CsF 0.456 g, 3.00 mmol
  • DME/MeOH 25 mL, 1:1
  • the desired product was prepared by replacing 4 -bromo-biphenyl-4-ol with Example
  • Example 30C 4-(6-f r(tians-4-hvdroxycvclohexyl)aminolmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yl)-3- methox y- 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and Example 30B in Example ID.
  • Example 31A 4 -Bromo-3-hvdroxymethyl-biphenyl-4-ol
  • the desired product was prepared by replacing 2-methoxy-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenol with 2-hydroxymethyl-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenol in Example 30A.
  • MS (DCI/NH 3 ) m/z: 278.0, 279.8 (M, M+2).
  • Example 3 IB 3-HvdroxymethvI-4 -(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-biphenyl-4-ol
  • the desired product was prepared by replacing 4-bromo-biphenyl-4-ol with Example 31 A in Example 29A.
  • Example 31C 4 -(6-(F(trans-4-hvdroxycvclohexyl)aminolmethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yP-3-
  • Example 32 3-methoxy-4 - ⁇ 6-F(neopentylamino)methyll-l,4-dihydroindenoFl,2-clpyrazol-3-yll-l,l - biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 15A and Example 30B in Example ID.
  • Example 33 4-(6-f F(3-hydroxy-2,2-dimethylpropyl)aminolmethyl ⁇ -l,4-dihydroindenoFl,2-clpyrazol-3-yP-3- methoxy- 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 17A and Example 30B in Example ID.
  • Example 34A 5-(allyloxy)-2-F(4-bromophenvP(hydroxy methylenel-l-indanone
  • the desired product was prepared by replacing terephthalic acid monomethyl ester with 4- bromo-benzoic acid in Example 22B.
  • Example 34B 6-Allyloxy-3-(4-biOmo-phenyP-l,4-dihvdro-indenoFl,2-clpyrazole The desired product was prepared by replacing Example 22B with Example 34A in Example 22C.
  • Example 34C 3-(4 -hydroxy- 1 , 1 -biphenyl-4-yP- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-6-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 35 3-(4'-hvdroxy-3 -mefhoxy- 1 , 1 '-biphenyl ⁇ -yP- 1 ,4-dihvdroindenoF 1.2-clpyrazol-6-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 2-methoxy-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 36 4 -F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-vn-l, -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 37A 3 -Iodo- 1 ,4-dihydro-indeno [ 1 ,2-clpyr azole
  • the desired product was prepared by replacing Example 1 A with l,4-dihydro-indeno[l,2- cjpyrazole, prepared according to procedure described in U.S. Patent 6297238, in Example IB.
  • Example 37B 4 '-( 1 ,4-dihydroindeno fl ,2-clpyrazol-3-yP- 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 37 A and Example 29A in Example ID.
  • Example 38 4 '- l " 6-(h ydrox ymeth yl)- 1 ,4-dihydroindeno I " 1 , 2-clp yrazol-3 -yll -3 -methoxy- 1 , 1 -biphen yl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and Example 30B in Example ID.
  • Example 39 3-(3 -fluoro-4-hvdroxy-l, -biphenyl-4-vP-l,4-dihvdroindenon,2-c1pyrazol-6-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 2-fluoro-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 40A 2-Amino-4-(4,4,5,5-tetramethyl-ri,3,21dioxaborolan-2-vP-phenol
  • Pd 2 (dba) 3 (0.0765 g)
  • Cy-MAP (0.165 g)
  • 1,4-dioxane 6 mL
  • 2-amino- 4-chloro-phenol (0.300 g, 2.09 mmol)
  • bis(pinacolato) diboron 0.557 g, 2.19 mmol
  • KOAc 0.308 g, 3.14 mmol
  • the reaction mixture was heated at 85 °C overnight, allowed to cool to room temperature, concentrated under reduced pressure and the residue was treated with EtOAc.
  • the ethyl acetate layer was washed with brine, dried over MgS0 4 , filtered, and the filtrate was concentrated under reduced pressure.
  • the residue was purified by flash chromatography eluting with hexanes/EtOAc (7:3 to 1:1) to give 0.273g (69%) of the desired product as brown solid.
  • Example 41 A 4-Bromo-4-hvdroxy-5-methoxy-biphenyl-2-carbaldehvde
  • 2-bromo-5-hydroxy-4-methoxy-benzaldehyde (1.00 g, 4.32 mmol)
  • 4- bromophenyl boronic acid (1.04 g, 5.18 mmol)
  • Pd(PPh 3 ) (0.250 g)
  • CsF (1.97 g, 12.6 mmol) in DME/MeOH (1:1, 65 mL) was heated at 70 °C overnight.
  • the mixture was diluted with CH 2 C1 2 and washed with water.
  • the organic layer was dried over MgSO , filtered, and the filtrate concentrated under reduced pressure.
  • Example 41B 4-Hvdroxy-5-methoxy-4'-(4,4,5,5-tetramethyl-n,3,21dioxaborolan-2-vP-biphenyl-2- carbaldehyde
  • the desired product was prepared by replacing 4'-bromo-biphenyl-4-ol with Example 41 A in Example 29A.
  • the product was carried into the next step without further purification.
  • Example 41C 4-hvdroxy-4'-r6-(hvdroxymethyl)-l,4-dihydroindenori,2-clpyrazol-3-yll-5-methoxy-l,r- biphenyl-2-carbaldehyde
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 41B in Example ID.
  • Example 42 3-(4-hvdroxy-l,r-biphenyl-4-vP-N-(trans-4-hydroxycvclohexyP-l,4-dihvdroindenori,2- clpyrazole-6-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 26B and Example 29A in Example ID.
  • the microwave assisted reaction was run for 450 to 2000 seconds at 160 to 180 °C.
  • Example 43 3-(4 '-hydroxy- 1 , 1 -biphenyl-4-vP-N-neopentyl- 1 ,4-dihydroindeno IT ,2-e1pyrazole-6-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 27A and Example 29A in Example ID.
  • Example 44A l,4-dihvdroindenon,2-c1pyrazole-7-carbaldehvde
  • the desired product was prepared by replacing 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole with 7-bromo-l,4-dihydro-indeno[l,2-c]pyrazole in Example 1 A.
  • Example 44B 3-iodo-l,4-dihydroindenoFl,2-c]pyrazole-7-carbaldehyde
  • the desired product was prepared by replacing Example IB with Example 44B in Example 19 A.
  • Example 44D 4-F7-(hvdroxyn ⁇ ethvP-l,4-dihydroindenoFl,2-cl ⁇ yrazol-3-vnbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 44C in Example ID.
  • Example 45 4- F7-(hydroxymethvP- 1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 -yllbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 46 4 -r7-(hydroxymethyl)-l,4-dihvdiOindenoFl,2-clpyrazol-3-yll-3-methoxy-l, -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and Example 30B in Example ID.
  • Example 47 N- ⁇ 3-F7-(hvdroxymethyP-l,4-dihvdroindenoFl,2-clpyrazol-3-yllphenyl
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and 3-acetamidobenzene boronic acid in Example ID.
  • Example 48 A 3-Iodo-7-morpholin-4-ylmethyl-l,4-dihvdro-indenoFl,2-c1pyrazole The desired product was prepared by replacing Example IB with Example 44B in Example 7A.
  • Example 48B 4-F7-(4-morpholinylmethyl)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzoic acid
  • Example 49 4-F7-(4-morpholinylmethyl)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzoic acid
  • MS (DCI/NH 3 ) m/z
  • Example 50 4-f 7- ⁇ F(2-hvdroxyethyl)aminolmethyl 1-1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)benzoic acid
  • Example 50A 2-F(3-Iodo- 1 ,4-dihydro-indenoFl ,2-clpyrazol-7-ylmethyl)-aminol-ethanol
  • the desired product was prepared by replacing Example IB and morpholine with Example 44B and 2-amino-ethanol in Example 7A.
  • Example 50B 4-(7-(F(2-hydroxyethyl)amino1methyl
  • the desired product was prepared by replacing Example IC with Example 50A in Example ID.
  • Example 51 4 -r7-(hydroxymethyl)-l ,4-dihydroindenoFl ,2-clpyrazol-3-yl1-l , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and Example 29A in Example ID.
  • Example 52A (2,2-Dimethyl-propyP-(3-iodo-l,4-dihydro-indenoFl,2-clpyrazol-7-ylmethyP-amine
  • the desired product was prepared by replacing Example IB and morpholine with Example 44B and neopentylamine in Example 7A.
  • Example 52B 4- ⁇ 7-F(neopentylamino)methyll- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-yl Ibenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 52A and 4-(4,4,5,5-teti"amethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 53 4 - ⁇ 7-r(neopentylamino)methyll- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3-yl ⁇ - 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 52A and Example 29 A in Example ID.
  • Example 54A 3-Iodo- 1 ,4-dihvdro-indeno F 1 ,2-clpyrazole-7-carboxylic acid
  • the desired product was prepared by replacing Example 2B with Example 44B in Example 26A.
  • Example 54B 3 -Iodo-1 ,4-dihvdro-indeno Fl ,2-clpyrazole-7-carboxylic acid methylamide
  • the desired product was prepared by replacing Example 22D and NH C1 with Example 54 A and methylamine in Example 23.
  • Example 54C 4-(7-Ffmethylamino)carbonyll-l,4-dihydroindenoFl,2-c1pyrazol-3-yl ⁇ benzoic acid
  • the desired product was prepared by replacing Example IC with Example 54B in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 55 3- F4-(aminocarbonypphenyll -N-methyl- 1 ,4-dihydroindeno F 1 ,2-c1pyrazole-7-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 54B and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 56 3-(4 -hydroxy- 1 , 1 -biphenyl-4-yl)-N-methyl- 1 ,4-dihvdroindeno F 1 ,2-clpyrazole-7-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 54B and Example 29A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 57 A 3 -Iodo- 1 ,4-dihy dro-indeno ⁇ 1 ,2-clp yrazole-7-carboxylic acid (2, 2-dimethyl-prop vP-amide
  • the desired product was prepared by replacing Example 22D and NH 4 C1 with Example 54A and neophentylamine in Example 23.
  • Example 57B 4-(7-F(neopentylamino)carbonyl1-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)benzoic acid
  • the desired product was prepared by replacing Example IC with Example 57A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 58 3-(4 -hydroxy- 1 , 1 '-biphenyl-4-vP-N-neopentyl- 1 ,4-dihydroindeno Fl ,2-clpyrazole-7-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 57A and Example 29A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 59A 3-Iodo- 1 ,4-dihydro-indenoFl ,2-clpyrazole-7-carboxylic acid (trans-4-hydroxy-cvclohexyP- amide
  • the desired product was prepared by replacing Example 22D and NH 4 CI with Example 54A and trans-4-amino-cyclohexanol in Example 23.
  • Example 59B 4-(7- ⁇ F( frans-4-hvdroxycyclohexyDaminolcarbonyl 1-1 ,4-dihvdroindenoF 1 ,2-clpyrazol-3- y benzoic acid
  • the desired product was prepared by replacing Example IC with Example 59A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 60A methyl 6-FF5-(allyloxy)-l-oxo-l,3-dihvdro-2H-inden-2-ylidene1(hydroxy)methyllnicotinate
  • the desired product was prepared by replacing terephthalic acid monomethyl ester with 5- (methoxycarbonyl)-2-pyridinecarboxylic acid in Example 22B.
  • Example 60B methyl 6-r6-(allyloxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yl1meotmate
  • the desired product was prepared by replacing Example 22B with Example 60A in Example
  • Example 60C 6-r6-(allyloxy -l,4-dihvdroindenoFl,2-clpyrazolC3-vnnicotinic acid
  • the desired product was prepared by replacing Example 22C with Example 60B in Example 22D.
  • the desired product was prepared by replacing Example 22C with Example 60B in Example 24.
  • Example 6 6-(6-hydroxy- 1 ,4-dihydroindeno Fl ,2-c1pyrazol-3-yl)nicotinic acid
  • the desired product was prepared by replacing Example 22C with Example 61 A in Example 22D.
  • Example 62A 4-FF5-(allyloxy)-l-oxo-l,3-dihydro-2H-inden-2-ylidenel(hydroxy)methyllbenzonitrile
  • the desired product was prepared by replacing terephthalic acid monomefhyl ester with 4- cyanobenzoic acid in Example 22B.
  • Example 62B 4-(6-Allyloxy-l,4-dihydro-indenoFl,2-clpyrazol-3-yl)-benzonitrile The desired product was prepared by replacing Example 22B with Example 62A in Example 22C.
  • Example 62C 6-(allyloxy)-3-r4-(lH-tetraazol-5-yl)phenvn-l,4-dihydroindenoFl,2-clpyrazole
  • a mixture of Example 62B (61.5 mg, 0.196 mmol), NaN 3 (19.1 mg, 0.294 mmol), and Et 3 N.HCl (40.5 mg, 0.294 mmol) in DMF (2 mL) was heated at 140 °C for 4 hours. To this mixture were added more NaN 3 (60.0 mg) and Et 3 N.HCl (120 mg). The reaction mixture was stirred overnight, cooled, and concentrated. The crude material was purified using the HPLC condition in Example 8 to give 20.0 mg (29%) of the desired product as brown solid.
  • Example 63 4-(6- ⁇ F(trans-4-methylcvclohexyPaminolmethyll-l,4-dihvdroindenori,2-clpyrazol-3-yl)phenol
  • the desired product was prepared by replacing 4-carboxybenzene boronic acid with 4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 64A (4-Bromophenyl)-imidazol- 1 -yl-methanone 4-Bromobenzoic acid (lOg, 50 mmol) in 50 ml of DMF was treated with carbonyl- 1,1'- dii idazole (18 g, 112.5 mmol). The mixture was stirred for 3 hours and poured into water. The mixture was filtered and the filter cake washed with water and dried to provide the title compound. MS (DCI/NH 3 ) m/z: 252.9 (M+H) + .
  • Example 64B 2-(4-Bromobenzoyl)-5 ,6-dimethoxy-indan- 1 -one 5,6-Dimethoxy-indan-l-one (2 g, 10.4 mmol) in 25 ml of THF was treated with NaH (60%, 624 mg, 15.6 mmol) at 0 °C. After the suspension was stirred at room temperature for 1 hour, the mixture was treated with Example 64A (2.61 g, 10.4 mmol) in 5 ml of THF dropwise. After stirring for 3 hours at room temperature, the mixture was poured into water and acidified with hydrochloric acid. The mixture was filtered and the filter cake was washed with water and recrystallized from ethanol to provide the title compound. MS (DCI/NH 3 ) m/z: 375.0 (M+H) + .
  • Example 64C 3-(4-Bromophenyl)-6,7-dimethoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • Example 64B (820 mg, 2.18 mmol), hydrazine monohydrate (0.127mL, 2.63 mmol), and acetic aicd (0.15 ml, 2.63 mmol) were combined in 30 ml of ethanol and heated at 90 °C for 6 hours. The mixture was allowed to cool to room temperature and filtered. The filter cake was dried to provide the title compound.
  • Example 64D 4'-(6,7-dimethoxy- 1 ,4-dihydroindenoFl ,2-c
  • Example 64C 50 mg, 0.14 mmol
  • 4-hydroxylphenyl boronic acid (23.3 mg, 0.17 mmol
  • Pd(PPh 3 ) 2 Cl 2 9.9 mg, 0.014mmol
  • Example 65 6,7-dimethoxy-3 - F4-( 1 H-tetraazol-5 -yDphenyll - 1 ,4-dihvdroindeno F 1 ,2-clpyrazole
  • Example 64C 50 mg, 0.14 mmol
  • zinc cyanide 17.4 mg, 1.48 mmol
  • Pd(PPh 3 ) 4 (15.6 mg, 0.014mmol) were combined in DMF (3 mL) in a capped 5 mL vial and heated at 180 °C for 300 seconds in a Smith Synthesizer. The mixture was cooled using 40 psi and then treated with sodium azide (105.3 mg, 1.62 mmol) and NH 4 C1 (87 mg, 1.62 mmol).
  • Example 66 4-(6,7-dimethoxy-l,4-dihydroindenoFl,2-e]pyrazol-3-yl)benzoic acid
  • Example 64C (78 mg, 0.21 mmol), PdCl 2 (dppf)-CH 2 Cl 2 (18 mg), triethyl amine (0.088 mL), were combined in THF (98 mL) and H 0 (1 mL) and stirred under a CO atmosphere (500 psi) at 120 °C for 16 hours. The mixture was allowed to cool to room temperature, concentrated under reduced pressure and the residue was purified by HPLC (for conditions, see Example ID) to provide the title compound. MS (DCI/NH 3 ) m/z: 337.0 (M+H) + .
  • Example 67A 2-(4-bromobenzoyl)-lH-indene-l,3(2H)-dione Methanol (8.5 ml) was treated with sodium (4.8 g) in benzene (90 mL). The reaction mixture was refluxed overnight, allowed to cool to room temperature, and treated with phthalic acid dimethyl ester (38.84 g) and l-(4-bromophenyl)ethanone (39.81 g) in benzene (50 mL). Distillation of the reaction mixture was performed at 80 °C overnight to remove methanol. The reaction mixture was poured into diluted HC1 and filtered. The filter cake was collected and recrystallized from ethanol to provide the title compound.
  • Example 67B 3 (4-bromophenyl)indeno F 1 ,2-clp yrazol-4( 1 H)-one
  • Example 67A (5.8 g) and hydrazine monohydrate (0.982 ml, 20.24 mmol) were combined in ethanol (300 mL) and refluxed at 90 °C overnight. The mixture was allowed to cool to room temperature and was filtered. The filter cake was dried to provide the title compound.
  • Example 67C butyl 4-(4-oxo- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3-vPbenzoate Pd(OAc) 2 (3.5 mg), Ph 3 P (16 mg), DIEA (2.6 ml), and Example 67B (100 mg) were combined in butanol and treated with a stream of CO for 5 minutes. The mixture was stirred at 120 °C overnight under a CO atmosphere. The mixture was allowed to cool to room temperature, concentrated, and the residue was purified by silicon gel chromatography using a mixture of hexane and ethyl acetate as eluent to provide the title compound. MS (DCI/NH 3 ) m/z: 347.0 (M+H) + .
  • Example 67D 4-(4-hydroxy- 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3-vPbenzoic acid
  • Example 67C (51 mg) in 2 ml of THF/MeOH (1:1) was treated with NaBH 4 (5.6 mg) at 0 °C. The reaction mixture was allowed to warm to room temperature and stir for 1 hour. The mixture was concentrated and the residue was suspended in THF (1 mL), MeOH (2 mL), and aqueous NaOH (IN, 1 mL). After stirring at 60 °C for 2 hours, the mixture was concentrated and the residue was purified by HPLC to provide the title compound. MS (DCI/NH 3 ) m/z: 293.3 (M+H) + .
  • Example 68A l,4-dihvdroindenoF1.2-c1pyrazole-6-carbaldehyde To a solution of 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (0.100 g, 0.425 mmol, see U.S. Patent 6297238 for preparation) in THF (3 mL) at -78 °C was added PhLi in cyclohexane/ether (1.8 M, 0.71 mL, 1.28 mmol) followed by s-BuLi in cyclohexane (1.3 M, 0.98 mL, 1.28 mmol) 30 minutes later.
  • the reaction mixture was stirred at -78 °C for 60 minutes and DMF (0.33 mL, 4.25 mmol) was added. The dry ice bath was removed after 30 minutes. After an additional 30 minutes, the reaction was quenched with water. The reaction mixture was extracted with EtOAc, washed with 50% brine, dried over MgS0 , filtered, and concentrated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (7:3 to 8:2) to give 0.053 g (68%) of the desired product as brown solid.
  • Example 68B 3-iodo-1.4-dihvdromdenoFl,2-elpyrazole-6-earbaldehyde
  • a suspension of Example 68A (7.90 g, 0.0429 mol) and N-iodosuccinimide (11.6 g, 0.0515 mol) in DMF (150 mL) was heated at 80 °C for 5.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was triturated with EtOAc and ether to give 7.20 g of brown solid as the desired product. The filtrate was concentrated and purified by flash chromatography eluted with EtOAc/hexane (7:3) to give 1.30 g of the desired product (combined yield: 64%).
  • Example 68C 3-iodo-6-(morpholin-4-ylmethvP- 1 ,4-dihvdroindeno Fl ,2-clpyrazole
  • a mixture of Example 68B (1.00 g, 3.22 mmol), morpholine (0.84 mL, 9.66 mmol), and TsOH.H 2 O (61.2 mg, 0.322 mmol) in toluene (50 mL) was heated to refluxing overnight. The solvent was evaporated. To the resulting residue were added EtOH (40 mL), THF (10 mL), and NaBH 4 (0.182 g, 4.83 mmol) at room temperature. The mixture was stirred overnight and the solid was filtered.
  • Example 68D 4'-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-vP-l,l -biphenyl-4-ol
  • Example 68E 4'-(6-morpholin-4-ylmethyl- 1 ,4-dihydro-indenoF 1 ,2-c1pyrazol-3-yl)-biphenyl-4-ol
  • a mixture of Example 68C (60.0 mg, 0.157 mmol), Example 68D (51.2 mg, 0.173 mmol), Na 2 CO 3 (1 M, 0.22 mL, 0.220 mmol), and Pd(PPh 3 ) 2 Cl 2 (11.0 mg, 0.0157 mmol) in DME/EtOH/H 2 O (7:2:3, 1.4 mL) in a capped 2 mL vial was heated to 160 to 170 °C for 450 to 600 seconds in a Smith Synthesizer (300W).
  • the reaction was cooled using 40 psi pressurized air. Solvents were evaporated and the crude product was purified using preparative HPLC to give 22.9 mg (22%) of the desired product as TFA salt.
  • the purification was processed on a Phenomenex® C18 column (250 mm X 21.2mm, 5 ⁇ m particle size) using a gradient of 0% to 70% acetonitrile : 0.1% aqueous TFA over 46 min at a flow rate of 25 mL/min.
  • Examples 69 to 83 represented by Figure (I) and listed in Table 1, were synthesized in a similar fashion as that described in Example 68E.
  • Example 84A 3-iodo-l,4-dihydroindenoFl,2-clpyrazole-6-carboxylic acid
  • KH 2 PO 4 5.26 g, 0.0387 mol
  • H2NSO3H 1.41 g, 0.0145 mol
  • H 2 0 15 mL
  • the reaction mixture was stirred for 15 minutes at 0 °C followed by the addition of NaHS03 (1.11 g, 0.0106 mol).
  • the resulting suspension was warmed to room temperature and stirred for 1 hour.
  • the reaction mixture was treated with N 2S 2 0 3 solution and concentrated to remove most of the solvents. Water was added to the resulting slurry and the suspension was stirred for 1 hour.
  • the solid material was filtered, rinsed with water, and dried in a vacuum oven to give 3.49 g of the desired product as yellow solid. This product was used in the following step without further purification.
  • Example 84B 3-iodo-6-(morpholin-4-ylcarbonyl)-l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared by substituting Example 68C with Example 84B in Example 68E.
  • the reaction temperature and time were raised to 180 °C and 1000 seconds, respectively.
  • Example 85A N-cyclohexyl-3-iodo- 1 ,4-dihydroindenoF 1 ,2-clpyrazole-6-carboxamide
  • a mixture of Example 84A (0.359 g, 1.07 mmol), HOBt (0.218 g, 1.61 mmol), EDC (0.308, 1.61 mmol), cyclohexylamine (0.18 mL, 1.61 mmol), and Et 3 N (0.22 mL1.61 mmol) in DMF (8 mL) was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and washed with NaHC0 3 and brine.
  • Example 85B N-cyclohexyl-3-(4'-hydroxy- 1 , 1 '-biphenyl-4-vD- 1 ,4-dihydroindenoF 1 ,2-clpyrazole-6- carboxamide
  • the desired product was prepared by substituting Example 68C with Example 85A in Example 68E.
  • the reaction temperature and time were raised to 180 °C and 1000 seconds, respectively.
  • Examples 86 to 97 represented by Figure (II) and listed in Table 2, were synthesized in a similar fashion as described in Example 84C or 85B.
  • Example 98A 6-bromo- 1 - ( F2-(trimethylsilvPethoxylmethyl I - 1 ,4-dihydroindeno F 1 ,2-clpyrazole and 6-bromo-2- ⁇ r2-(trimethylsilyl)ethoxylmethyll-2,4-dihydroindenoFl,2-c1pyrazole
  • 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (4.08 g, 0.0174 mol, see U.S. Patent 6297238 for preparation) in DMF (100 mL) at 0 °C was added NaH (60%, 0.764 g, 0.0191 mol).
  • Example 98 B N-d - ( F ⁇ -ftrimethylsilvDethoxyl methyl 1-1 ,4-dihydroindeno Fl ,2-clpyrazol-6-yl)acetamide
  • Pd(OAc) 2 70.9 mg, 2 mol%)
  • Xantphos 274 mg, 3 mol%
  • Cs 2 CO 3 7.72 g, 0.0237 mol
  • acetamide 1.12 g, 0.0190 mol
  • Example 98D 2-chloro-N- 1 ,4-dihydroindeno Fl ,2-clpyrazol-6-ylacetamide
  • acetone 10 mL
  • saturated NaHCO 3 solution 5 mL
  • chloroacetyl chloride 0.13 mL, 1.61 mmol
  • the solvent was partially evaporated and water was added to the suspension.
  • the solid was filtered, washed with water, and dried to give the desired product (0.280 g, 78%) as off-white solid.
  • Example 98E 2-chloro-N-(3-iodo-l,4-dihvdroindenoFl,2-c1pyrazol-6-vPacetamide To a solution of Example 98D (0.140 g, 0.565 mmol) in DMF (3 mL) was added NIS (0.153 g, 0.678 mmol) and the mixture was heated at 80 °C for 4 hours and cooled. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed water, brine, dried, filtered, and concentrated, and purified by flash chromatography eluted with EtOAc/hexane (7:3 to 9:1) to give 47 mg of the desired product as brown solid.
  • Example 98F N-O-iodo-l -dihydroindenoF ⁇ -clpyrazol- ⁇ -yP ⁇ -morpholin ⁇ -ylacetamide
  • EtOH 2 mL
  • morpholine 31.3 ⁇ L
  • the solvent was evaporated and the residue was purified by flash chromatography eluted with EtOAc to give 39.5 mg (78%) of the desired product as yellow foam.
  • Example 98G N- F3-(4 -hydroxy- 1 , 1 -biphenyl-4-vP- 1 ,4-dihydroindeno F 1 , 2-clpyrazol-6-yll-2-morpholin-4- ylacetamide
  • the desired product was prepared by substituting Example 68C with Example 98F in Example 68E.
  • Examples 99 to 103 represented by Figure (III) and listed in Table 3, were synthesized in a similar fashion as described in Example 98G.
  • Example 104 A 2-(hvdroxymethylene -6-n ethoxyindan- 1 -one To a mixture of ethyl formate (15.75 mL, 0.195 mol) and NaH (60%, 7.80 g, 0.195 mol) in benzene (550 mL) was added a suspension of 6-methoxy-indan-l-one (15.81 g, 0.0974 mol) in benzene (150 mL) dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight and treated with water. The solid was filtered, washed with water, and oven dried to give the desired product (16.86 g, 91%).
  • Example 104B 7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • a mixture of Example 104A (16.86 g, 0.0886 mol), hydrazine monohydrate (5.2 mL, 0.106 mol), and AcOH (6.1 mL, 0.106 mol) in EtOH (375 mL) was heated at 90 °C for 2 hours. The solvent was evaporated and the residue was triturated with water and filtered. The filtering cake was triturated again with NaHC0 3 solution, filtered, washed with water, and oven dried to give the desired product (13.9 g, 84%).
  • Example 104C 6-bromo-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyr azole
  • a solution of Example 104B (8.91 g, 0.0478 mol) in AcOH (150 mL) was added Br (3.43 mL, 0.0669).
  • the reaction mixture was concentrated after 5 minutes and the residue was triturated into EtOAc and hexane, and then filtered.
  • the solid was stirred in NaHCO 3 solution and filtered, washed with water, and oven dried to give the desired product (11.99 g, 95%).
  • the material with slight impurity was used in the next step without further purification.
  • MS (DCI/NH3) m/z: 265.0 (M+H) + ; 266.9 (M+H+2) + .
  • Example 104D 7-methoxy-l,4-dihvdroindenoFl,2-c]pyrazole-6-carbaldehyde
  • PhLi 1.9 M, 21.8 mL, 0.0414 mol
  • s-BuLi 1.4 M, 29.6 mL, 0.0414 mol
  • DMF 12.8 mL, 0.166 mol
  • Example 68 A The desired product was prepared by substituting Example 68 A with Example 104D in
  • Example 104F 3-iodo-7-methoxy-l,4-dihydroindenoFl,2-clpyrazole-6-carboxylic acid
  • the desired product was prepared by substituting Example 68B with Example 104E in Example 84A.
  • the crude product was used in the next step without further purification.
  • Example 104G The desired product was prepared by substituting Example 84A and cyclohexylamine with Example 104F and 4-(aminomethyl)pyridine in Example 85 A. The slightly impure product was used in the next step without further purification. MS (DCI/NH 3 ) m/z: 447.0 (M+H) + . The formation of tertiary amides in this step towards corresponding final compounds listed in Table 4 was done following the protocol in Example 84B.
  • Example 104H 3-(4'-hydroxy- 1 , 1 -biphenyl-4-yP-7-methoxy-N-(pyridin-4-ylmethyP-l ,4-dihydroindenoF 1 ,2- clpyrazole-6-carboxamide
  • the desired product was prepared by substituting Example 68C with Example 104G in Example 68E.
  • Example 105 A 2-F(3-Iodo-7-methoxy-l,4-dihvdro-indenoFl,2-clpyrazol-6-ylmethyl)-amino1-ethanol
  • the desired product was prepared by substituting Example 68B and morpholine with Example 104D and 2-aminoethanol in Example 68C.
  • the slightly impure product was used in the next step without further purification.
  • the desired product was prepared by substituting Example 68C with Example 105 A in Example 68E.
  • Examples 106 to 116 represented by Figure (IV) and listed in Table 4, were synthesized in a similar fashion as described in Example 104H or Example 105B.
  • Example 117A (3-iodo- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-yl)methanol
  • a suspension of Example 68B (0.500 g, 1.61 mmol) in a mixture of MeOH (9 mL) and THF (3 mL) was added NaBH (73.0 mg, 1.93 mmol) at room temperature.
  • the mixture was stirred for 2 hours and the solvent was evaporated.
  • the desired product (0.324 g, 65%) was recrystalized from hot CH 2 C1 2 with a small amount of MeOH.
  • Example 117B 3-fluoro-4 -F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yll-l, -biphenyl-4-ol
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 117A and 2-fluoro-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol respectively in Example 68E.
  • Example 123 A 3-iodo-l- ⁇ F2-(trimethylsilvPethoxylmethyl)-l,4-dihydroindenoFl,2-c1pyrazole-6-carbaldehvde
  • SEMC1 0.63 mL, 3.55 mmol
  • Example 123B 3-iodo-6- F(4-methylpiperazin- 1 -v methyll - 1 - ⁇ F2-(trimethylsilyl)ethoxylmethyl j - 1 ,4- dihydroindenoFl,2-clpyrazole
  • the desired product was prepared by substituting Example 68B and morpholine with Example 123A and 1-methylpiperazine respectively in Example 68C.
  • n-BuLi 1.6M in hexane, 41.4 mL, 0.0663 mol
  • Example 123D 3-(6-fluoropyridin-3 -yP-6- F(4-methylpiper azin- 1 -yPmethyll- 1 - ⁇ F2- (trimethylsilypethoxylmethyl ⁇ - 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 123B and Example 123C in Example 68E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 494.3 (M+H) + .
  • Example 123E 5- ⁇ 6-F(4-methylpi ⁇ erazin-l-yl methyn-1.4-dihydroindenoFl,2-clpyrazol-3-yl
  • Example 124 3-(6-cyanopyridin-3-yP-N-(pyridm-2-ylmethyl)-l,4-dihydroindenoFl,2-clpyrazole-6- carboxamide
  • Example 124 A 3-iodo-N-(pyridin-2-ylmethyl)-l,4-dihvdroindenoF1.2-c1pyrazole-6-carboxamide
  • the desired product was prepared by substituting cyclohexylamine with 2- (aminomethyl)pyridine in Example 85A. CH 2 CI2 was used for trituration.
  • Example 124B l-Fbis(4-methoxyphenyl)methyll-3-iodo-N-(pyridin-2-ylmethvP-l,4-dihvdroindenoFl,2- clpyrazole-6-carboxamide
  • a mixture of Example 124A (0.176 g, 0.423 mmol), bis-(4-methoxy-phenyl)-methyl chloride (0.122 g, 0.465 mmol), and Et 3 N (71 ⁇ L, 0.507 mmol) in DMF (2.0 mL) was sti ⁇ -ed at room temperature for 4 hours.
  • the reaction mixture was diluted with 50% brine and extracted with EtOAc.
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 124B and Example 123C in Example 67E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 612.2 (M+H) + .
  • Example 124D 3-(6-cyanopyridin-3-vP-N-( ⁇ yridin-2-ylmethvP-1.4-dihydroindenoFl,2-clpyrazole-6- carboxamide
  • the desired product was prepared by substituting Example 123D with Example 124C in Example 123E. Acidic deprotection was done in EtOH and 1,4-dioxane at 40 °C overnight.
  • Examples 125 to 129 represented by Figure (VI) and shown in Table 6, were synthesized in the similar fashion as described in Example 123E or Example 124D.
  • the pyrazole nitrogen of the intermediates could also be protected by SEM group.
  • Example 130 A (3-iodo- 1 - ( F2-(trimethylsilyl)ethoxylmethyl 1 - 1 ,4-dihydroindeno Fl ,2-clpyrazol-6-vPmethanol
  • NaBH 4 (64.5 mg, 1.70 mmol)
  • Example 130B (3-(6-fluoropyridin-3-yl)-l-f r2-(trimethylsilyl)ethoxylmethyl
  • Example 130C 5-F6-(hydroxymethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridine-2-carbonitrile
  • the desired product was prepared by substituting Example 123D with Example 130B in Example 123E.
  • Example 131 A 5-(6-(hvdroxymethvP-l- ⁇ F2-(trimethylsilvPethoxylmethyl)-l,4-dihvdroindenoFl,2-c1pyrazol-3- yl)pyridine-2-carbonitrile
  • the desired product was prepared by substituting Example 123D with Example 130B in Example 123E except that the final removal of SEM protecting group using HCl was not performed.
  • a mixture of Example 131 A (60.0 mg, 0.143 mmol), di-t-butyl azodicarboxylate (39.6 mg, 0.172 mmol), Ph 3 P on solid support (3mmol/g, 57.3 mg, 0.172 mmol), and 3- hydroxypyridine (16.4 mg, 0.172 mmol) in THF (2 mL) was stirred at room temperature overnight. The solid was filtered and the solvent was evaporated. The crude product was treated with HCl (concentrated, 4 drops) and EtOH (4 mL).
  • Example 132 5- ⁇ 6-F(pyridin-4-yloxy)methvn-l,4-dihvdroindenoFl,2-clpyrazol-3-yllpyridine-2-carbonitrile
  • the desired product was prepared by substituting 3-hydroxypyridine with 4- hydroxypyridine in Example 13 IB.
  • Example 133 3-(6-fluoropyridin-3-yl)-7-methoxy-4,4-dimethyl-l,4-dihvdroindenoFl,2-c1pyrazol-6-ol
  • Example 133 A 6-methoxy-3 ,3-dimethyl-5- ⁇ F2-(trimethylsilyl)ethoxylmethoxy 1 indan- 1 -one
  • 5-hydroxy-6-methoxy-3,3-dimethyl-indan-l-one (40.0 g, 0.194 mol, see preparation in J. Chem. Soc. Perkin Trans.
  • Example 133B 2-(hvdroxymethylene)-6-methoxy-3 ,3-dimethyl-5- ⁇ F2-(trimethylsilvPethoxylmethoxy 1 indan- 1 - one
  • NaH 60%, 0.343 g, 8.58 mmol
  • ethyl formate 0.73 mL, 8.58 mmol
  • a mixture of Example 133B (0.886 g, 2.43 mol), hydrazine monohydrate (0.14 mL, 2.92 mol), and AcOH (38 ⁇ L, 0.729 mmol) in EtOH (20 mL) was heated at 85 °C for 1.5 hours. The solvent was evaporated and the residue was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 0.865 g of the desired product as yellow solid.
  • Example 133D 3-iodo-7-methoxy-4,4-dimethyl-6- ⁇ F2-(trimethylsilvPethoxy1methoxy)-l,4-dihvdroindenoFl,2- clpyrazole
  • a suspension of Example 133C (10.4 g, 0.0290 mol) and N-iodosuccinimide (7.82 g, 0.0348 mol) in 1,4-dioxane (300 mL) was heated at 90 °C for 7.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 8.79 g of the desired product.
  • Example 133E 3-(6-fluorop yridin-3-yl)-7-methoxy-4,4-dimethyl- 1 ,4-dihydroindenoF 1 ,2-c1pyrazol-6-ol
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 133D and Example 123C in Example 68E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. This intermediate was treated with HCl (concentrated, 3 drops) and EtOH (2 mL). The mixture was stirred at room temperature for 2 hours. The solvent was evaporated and the residue was purified using reversed-phase HPLC to give the desired product (13.0 mg) as TFA salt.
  • Example 134 5-f6-hvdroxy-7-methoxy-4,4-dimethyl-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)pyridine-2- carbonitrile
  • Example 134A 3-iodo-7-methoxy-4,4-dimethyl-6- ⁇ F2-(trimethylsilvPethoxylmethoxy I - 1 - ( F2- (trimethylsilyPethoxylmethyl I- 1 ,4-dihvdroindeno Fl ,2-clpyrazole
  • SEMCl 0.19 mL, 1.07 mmol
  • Example 134B 3-iodo-7-methoxy-4,4-dimethyl-l-f F ⁇ -CtrimethylsilyPethoxylmethyll-l -dihydroindenoFl ⁇ - clpyrazol-6-ol
  • a mixture of Example 134A (0.450 g, 0.730 mmol) and HCl (concentracted, 0.4 mL) in EtOH (10 mL) was stirred at room temperature for 3 hours. The solvent was evaporated at room temperature and the residue was purified by flash chromatography eluted with hexane/EtOAc/CH 2 Cl 2 (7:3:1 to 1:1:0) to give 0.321 g (90%) of the desired product as pale yellow gel.
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 134B and Example 123C in Example 68E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 456.1 (M+H) + .
  • Example 134E 5-(6-hydroxy-7-methoxy-4,4-dimethyl-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridine-2- carbonitrile
  • a mixture of Example 134D (23.0 mg, 0.0497 mmol) and HCl (concentrated, 2 drops) in EtOH (2 mL) was stirred at 75 °C for 1.5 hours.
  • the solvent was evaporated and the residue was purified using reversed-phase HPLC to give the desired product (4.0 mg) as TFA salt.
  • Example 135 A 3-iodo-7-methoxy-4 ,4-dimethyl-6-(pyridin-3-ylmethoxy)-l- ⁇ F2-(trimethylsilyl)ethoxylmethyl ⁇ - l,4-dihvdroindenoF1.2-clpyrazole
  • Example 135C 5-F7-methoxy-4,4-dimethyl-6-(pyridin-3-ylmethoxy)- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3- yllpyridine-2-carbonitrile
  • the desired product was prepared by substituting Example 123D with Example 135B in Example 123E.
  • Examples 136 to 142 represented by Figure (VII) and shown in Table 7, were synthesized in a similar fashion as Example 135C.
  • Example 143A 6-methoxy-5-( F2-(trimethylsilyl)ett ⁇ oxylmethoxy 1 indan- 1 -one
  • 5-hydroxy-6-methoxy-indan-l-one (21.1 g, 0.118 mol, see preparation in 3. Org. Chem. 57, 1992, 589-594) and N,N-diisopropylethylamine (21.6 mL, 0.124 mol) in CH 2 C1 2 (200 mL) was added SEMCl (21.3 mL, 0.121 mol). The mixture was stirred at room temperature for 2 hours and diluted with NaHCO 3 solution.
  • Example 143B phenyl 6-chloronicotinate A mixture of 6-chloronicotinic acid (68.0 g, 0.431 mol), phenol (40.6 g, 0.431 mol), DCC (93.6 g, 0.453 mol), and DMAP (1.60 g, 0.0129 mol) in ether (1 L) was stirred at room temperature overnight. The solvent was evaporated and the residue was stirred in CH 2 C1 2 . The solid was filtered and the filtrate was purified by flash chromatography eluted with CH 2 CI 2 10 give 88.0 g (88%) of the desired product.
  • Example 143C 3-(6-chloropyridin-3-yl)-7-methoxy-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy 1-1,4- dihydroindenoF 1 ,2-clpyrazole
  • NaH 60%, 9.37 g, 0.234 mol
  • Example 143B 21.0 g, 0.0898 mol
  • Example 143D The desired product was prepared by substituting Example 68A with Example 143C in Example 123A. MS (ESI) m/z: 574.2 (M+H) + .
  • Example 143E 5-(7-methoxy-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy I - 1 - ⁇ F2-(trimethylsilyPethoxylmethyl 1-1,4- dihydroiiidenoFl,2-clpyrazol-3-yPpyridine-2-carbonitrile
  • Example 143G 5-F7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihvdroindenoFl,2-c1pyrazol-3-yllpyridine-2- carbonitrile
  • the desired product was prepared by first substituting Example 134B and 3- pyridylcarbinol with Example 143F and 2-pyridylcarbinol in Example 135A.
  • the intermediate was treated with HCl and EtOH at about 75 °C for about 2 hours.
  • the suspension was cooled and the solid was filtered, washed with ether, and dried to give the desired product as HCl salt.
  • the intermediate after acidic treatment was purified using reversed-phase HPLC to give the desired product as TFA salt.
  • Example 144B 6-hy droxy-5 -methox yindan- 1 -one A mixture of Example 144A (28.5 g, 0.173 mol), Mel (27.0 mL, 0.433 mol), and Li 2 CO 3 (32.0 g, 0.519 mol) in DMF (800 mL) was heated at 55 °C overnight. DMF was evaporated and the residue was treated with water (IL) and HCl (concentrated, 60 mL). The solid was filtered, washed with water until the filtrate became neutral, and dried to give 21.0 g (68%) of the desired product.
  • IL water
  • HCl concentrated, 60 mL
  • Example 144C 5- ⁇ 7-F(6-chloropyridin-3-yl)methoxyl-6-methoxy-l,4-dihydroindenoFl,2-clpyrazol-3- yl lpyridme-2-carbonitrile
  • the desired product was prepared by substituting 6-hydroxy-5-methoxyindan-l-one with Example 144B in Example 143A followed by the similar procedures in Examples 143C, 143D, 143E, 143F, and 143G.
  • Examples 145 to 163 represented by Figure (VIII) and shown in Table 8 were synthesized in a similar fashion as described in Example 143G or 144C.
  • Example 164 4'-(6,7-dimethoxy-l,4-dihydromdenoFl,2-c1pyrazol-3-yl)-3-methoxy-l, -biphenyl-4-ol
  • Example 64C 50 mg, 0.14 mmol
  • 2-methoxy-4-(4,4,5,5-tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol (42.3 mg, 0.17 mmol)
  • Pd(PPh 3 ) 2 Cl 2 9.9 mg, 0.014mmol
  • Example 165 A 4-Benzyloxybenzoic acid (2 g, 8.76 mmol) and Ll'-carbonyldiimidazole (2.3 g, 14 mmol) were combined in DMF. The reaction mixture was stirred overnight and poured into ice- water. The resulting precipitate was collected by filtration, washed with water, and dried. The title product (2.4 g) was obtained at 99% yield. MS (DCI/NH 3 ) m/z: 279.08 (M+H) + .
  • Example 165B 2-F4-(benzyloxy)benzovn-5 ,6-dimethoxyindan- 1-one 5,6-Dimethoxyindanone (1 g, 5.2 mmol) in 45 mL of THF was treated with NaH (60%, 312 mg, 7.8 mmol). After the addition of Example 165A (1.45 g, 5.2 mmol), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. Yellow solid was collected by filtration, washed with water and hot ethanol. The title product (1.2 g) was obtained at 57% yield. MS (DCI/NH 3 ) m/z: 403.11 (M+H) + .
  • Example 165B 500 mg, 1.24 mmol
  • hydrazine monohydrate 72 ⁇ L
  • acetic acid 85 ⁇ L
  • the precipitates were collected by filtration to give the title compound.
  • Example 165D 4-(6,7-dimethoxy-l ,4-dihydroindenoF 1 ,2-clpyrazol-3-yl)phenol
  • Example 165C (57 mg, 0.14 mmol) and Pd/C (10%, 15.2 mg) were combined in THF (20 mL) and stirred under hydrogen atmosphere for 24 hours. Pd/C was removed by filtration and the filtrate was concentrated. The residue was purified by HPLC to give the title compound. MS (DCI/NH 3 ) m z: 309.03 (M+H) + .
  • Example 166 A 3-(4-bromophenyl)-l,4-dihydroindenoFl,2-clpyrazole-6,7-diol
  • Example 64C (142 mg, 0.38 mmol) in 1,2-dichloroethane (50 mL) was treated with BBr 3 *SMe 2 (597 mg, 1.91 mmol), heated at 80°C for 30 hours and cooled. Reaction was quenched with water (20 mL), and the resulting mixture was treated with ether (100 mL). The precipitate was collected by filtration and further purified by HPLC. MS (DCI/NH3) m/z: 344.94 (M+H) + .
  • Example 166B 3-(4 -hydroxy- 1 , 1 -biphenyl-4-vP- 1 ,4-dihydroindeno F 1 ,2-clpyrazole-6,7-diol
  • Example 166A 35 mg, 0.10 mmol
  • 4-hydroxyl ⁇ henyl boronic acid 18 mg
  • Na 2 CO 3 (1 M, 0.25 mL
  • Pd(PPh 3 ) 2 Cl 2 9.9 mg, 0.014mmol
  • Example 167 4-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)benzonitrile
  • Example 168A l-(6-methoxy-2-naphthovP-lH-imidazole 6-Methoxynanphthalene-2-carboxylic acid (2 g, 9.9 mmol) and i'-carbonyldiimidazole (2.4 g, 14.8 mmol) were combined in DMF ( 10 mL) and stirred overnight. The white solid was collected by filtration, washed with water and dried to give the title compound.
  • Example 168B 5-(benzyloxy)-2-(6-methoxy-2-naphthoyPindan-l-one 5-Benzyloxyindanone (1.5 g, 6.29 mmol) was treated with NaH (60%, 377 mg) in THF (50 mL), and then Example 168A (1.59 g) was added. The reaction was stirred for 6 hours at room temperature. The precipitates were collected by filtration and dissolved in water, acidified with concentrated HCl, and the resulting precipitates were collected, washed with water and dried to give the title compound.
  • Example 168C 6-(benzyloxy)-3-(6-methoxy-2-naphthvP-l,4-dihydroindenoFl,2-clpyrazole
  • Example 168D 3-(6-hydroxy-2-naphthyl)- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-ol
  • Example 169 6,7-dimethoxy-3-F4-(lH-pyrrol-2-yl)phenyll-l,4-dihydroindeno ⁇ ,2-clpyrazole
  • the desired product was prepared using the procedure in Example 164 replacing 2- methoxy-4-(4,4,5,5-tertramethyyl[l,3,2] dioxaborolan-2-yl)-phenol with l-tert-Bocpyrrolyl-2- boronic acid.
  • MS (DCI/NH 3 ) m/z: 358.12 (M+H) + .
  • Example 170 A l-Fchloro(4-methoxyphenyl)methyll-4-methoxybenzene Bis(4-methoxyphenyl)methanol (30 g) was treated with thionyl chloride (40 mL). The resulting mixture was refluxed for 2.5 hours and concentrated to give the desired product.
  • Example 170B 1 - rbis(4-methoxyphenyl)methyH-4-iodo- lH-pyrazole 4-Iodo-lH-pyrazole (1 g, 5.15 mmol), Example 170A (1.49 g, 5.67 mmol), and triethylamine (0.79 mL) were combined in THF (20 mL), and refluxed for 1.5 hour. The inorganic salts were removed by filtration, and the filtrate was concentrated. The residue was recrystalized from a mixture of ethyl acetate and hexane to give 1.56 g of product at 72% yield. MS (DCI/NH 3 ) m/z: 420.0 (M+H) + .
  • Example 170C 1 - rbis(4-methoxyphenvPmethvn-3-(4-bromophenyl)-6,7-dimethoxy- 1 ,4-dihvdroindeno F 1 ,2- clpyrazole
  • the desired product was prepared using the procedure in Example 170B replacing 4- iodo-lH-pyrazole with Example 64C.
  • the title product (2.0 g) was obtained at 83% yield.
  • MS (DCI/NH3) m/z: 597.12 (M+H) + .
  • Example 170D 1 -Fbis(4-methoxyphenyPmethyl1 -6,7-dimethoxy-3-F4-(4,4,5 ,5 -tetramethyl- 1 ,3,2-dioxaborolan-2- yPphenyll - 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • Example 170C (1 g, 1.67 mmol), bis(pinacolato)diborane (467 mg, 1.84 mmol), PdCl 2 (dppf CH 2 Cl 2 (41 mg, 0.05 mmol), dppf (28 mg), and K OAc were combined in 1,4- dioxane (35 mL) and purged with a stream of nitrogen.
  • Example 170E l-Fbis(4-methoxyphenyl)methyll-3-(4- ⁇ l-Fbis(4-methoxyphenyPmethyn-lH-pyrazol-4- yl ⁇ phenvP-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole
  • Example 170B (67 mg, 0.159 mmol)
  • Example 170D (84 mg, 0.13 mmol), Na 2 C ⁇ 3 (1 M, 0.3 mL), and Pd(PPh 3 )2Cl 2 (9.9 mg, 0.014 mmol) were combined in DME/EtOH/H 2 O (7:2:3, 1.5 L) in a capped 2 mL vial and heated to 160 °C for 1000 seconds in a Smith Synthesizer.
  • Example 170E (60 mg, 0.078 mmol) was treated with 4 M HCl in dioxane (5 mL). The reaction was stirred overnight and concentrated. The residue was washed with a mixture of hexane and ethyl acetate to give light yellow product. MS (DCI/NH3) m/z: 359.07 (M+H) + .
  • Example 171 4'-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yP-l, -biphenyl-4-yl l,4'-bipiperidine- - carboxylate
  • Example 171 A 4 - ⁇ l-Fbis(4-methoxyphenyPmethyll-6,7-dimethoxy- 1 ,4-dihydroindenoF l,2-clpyrazol-3-yl 1-1,1' biphenyl-4-ol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 170C. However, the product was purified by flash chromatography instead of HPLC. The title product (168 mg) was obtained at 82% yield. MS (DCI/NH3) m/z: 611.24 (M+H) + .
  • Example 171A 150 mg, 0.25 mmol
  • pyridine 4 mL
  • [l,4']bipiperidinyl-l'-carbonyl chloride 190 mg, 3 mmol
  • Example 17 IC 4'-(6.7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-vP-l, -biphenyl-4-yl l,4'-bipiperidine-r- carboxylate
  • Example 171B (90 mg, 0.11 mmol) in dichloromethane was treated with TFA (4.5 mL), and the reaction was stirred overnight and concentrated. The residue was purified by preparative HPLC. The title product (50 mg) was obtained at 56% yield. MS (DCI ⁇ NH3) m/z: 579.30 (M+H) + .
  • Example 172 A 5 -hydroxy-6-methoxyindan- 1 -one 5,6-Dimethoxy-l-indanone (1 g, 5.20 mmol) and NaCN (2.55g, 52 mmol) were combined in DMSO (10 mL). The reaction was stirred at 100°C for two days, cooled, diluted with water and extracted with dichloromethane. The aqueous solution was acidified with concentrated HCl, and extracted with dichloromethane. The organic layer was dried over MgSO and evaporated to give the title compound (500 mg). MS (DCI/NH 3 ) m/z: 178.99 (M+H) + .
  • Example 172B 6-methoxy-5-F(4-methoxybenzvPoxylindan-l-one
  • Example 172A (1.4 g, 7.86 mmol), 4-methoxybenzyl chloride (2.13 g, 15.72 mmol), Na 2 CO 3 (1.67 g, 15.72) and sodium iodide (1.18 g, 7.86) were combined in acetone (50 mL). The reaction was stirred for 3 days, and then the solvent was removed. The residue was mixed with water (300 mL) and ethyl acetate (100 mL).
  • Example 172C 2-(4-bromobenzoyl)-6-methoxy-5-F(4-methoxybenzyl)oxylindan-l-one
  • Example 172B (1.2 g, 4.0 mmol) in 40 mL of THF was treated with NaH (60%, 240 mg, 6.0 mmol). After the addition of Example 64A (1.31 g), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. The precipitate was collected by filtration and recrystallized from ethanol. The title product (1.7 g) was obtained at 88% yield. MS (DCI/NH3) m/z: 481.04 (M+H) + .
  • Example 172D 3-(4-bromophenvP-7-methoxy-6-F(4-methoxybenzvPoxy1-l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 172C.
  • the title compound (1.45 g) was obtained at 92% yield.
  • Example 172E 3-(4-bromophenvP-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazol-6-ol
  • Example 172D (280 mg, 0.59 mmol) in HO Ac (35 mL) was heated at 90°C for 24 hours, and the solvent was evaporated. The residue was triturated with a mixture of hexane and ethyl acetate to give the title product (220 mg) at 90% yield.
  • Example 173 3-(4 -hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy- 1 ,4-dihydroindenoFl ,2-clpyrazol-6-ol
  • MS DCI/NH3 m/z: 371.14 (M+H) + .
  • Example 175 4 '- F7-methoxy-6-(pyridin-2-ylmethoxy)- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazol-3-yll -1,1 -biphenyl-4- ol
  • Example 175A 5-(benzyloxy)-6-methoxyindan-l-one
  • Example 172A (15 g, 84.3 mmol), benzyl bromide (15 mL, 126.3 mmol), and K2CO 3 (23.25 g, 168.5 mmol) were combined in acetone (50 mL). The reaction was stirred for 2 days, and the inorganic salt was removed by filtration. The filtrate was concentrated, and the residue was recrystallized from a mixture of hexane and ethyl acetate to give the title product (17.1 g) at 76% yield. MS (DCI/NH3) m/z: 269.11 (M+H) + .
  • Example 175B 5-(benzyloxy)-2-(4-bromobenzoyl)-6-methoxyindan- 1 -one
  • the desired product was prepared using the procedure in Example 172C replacing Example 172B with Example 175A.
  • Example 175C 6-(benzyloxy -3-(4-bromophenyP-7-methoxy-l,4-dihydroindenoFl,2-clpyrazole
  • Example 175D 6-(benzyloxy)-3-(4-bromophenyP-7-methoxy-l- ⁇ F2-(trimethylsilvPethoxylmethyl
  • NaH 60%, 1.21 g, 30.25 mmol
  • DMF 150 mL
  • SEMCl 5.35 mL, 30.25 mmol
  • the reaction was stirred for 2 hours and poured into ice- water. The precipitate was collected by filtration and dried to give the title product (15.0 g) at 94% yield.
  • Example 175E 4'-(6-(benzyloxy)-7-methoxy- 1 - ⁇ F2-(trimethylsilyl)ethoxy1methyl ⁇ -l ,4-dihydroindeno Fl ,2- clpyrazol-3-yl)-l , 1 -biphenyl-4-ol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 175D.
  • MS (DC-yNH 3 ) m/z: 591.27 (M+H) + .
  • Example 175G 7-methoxy-3-(4 -(F2-(trimethylsilyl)ethoxylmethoxyl-l,l'-biphenyl-4-vP-l-(F2-
  • Example 175H 4'-r7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3-vn-l,r-biphenyl-4- ol
  • Example 175G 50 mg, 0.0792 mmol
  • Cs 2 CO 103 mg, 0.317 mmol
  • 2-chloromethylpyridine*HCl 14.3 mg, 0.087 mmol
  • Example 175G 50 mg, 0.0792 mmol
  • di-tert-butyl azodicarboxylate 44 mg, 0.19 mmol
  • polymer-supported Ph 3 P 3 mmol/g, 63 mg, 0.19 mmol
  • pyridin-3-yl-methanol 22 mg, 0.20 mmol
  • THF 3 mL
  • the reaction was stirred at room temperature for 3 days, and the insoluble material was removed by filtration and washed with THF thoroughly.
  • the filtrate was concentrated, and the residue was suspended in methanol (2 mL), treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours.
  • the precipitate was collected by filtration to give the title compound.
  • the filtrate was concentrated, and the residue was purified by HPLC to give another portion of the title compound.
  • Examples 190 to 204 represented by Figure (X) and shown in Table 10 were synthesized in a similar fashion as described in Example 189, except substituting the appropriate alcohol for pyridin-3-yl-methanol.
  • Example 205A 6-methoxy-5-(F2-(trimethylsilyl)ethoxy1methoxylindan-l-one
  • Example 172A (1 g, 5.62 mmol) and N,N-diisopropylethylamine (2.94 mL, 16.86 mmol) were combined in dichloromethane and treated with SEMCl (1.49 mL, 8.43 mmol). The reaction mixture was stirred for 1 hour, diluted with dichloromethane, washed with cold water and saturated NaHCO 3 . The organic layer was dried over MgSO and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (1.3 g) was obtained at 75% yield. MS (DCI/NH 3 ) m/z: 309.1 (M+H) + .
  • Example 205B 4-(lH-imidazol-l-ylcarbonyl)benzonitrile The desired product was prepared using the procedure in Example 165A replacing 4- benzyloxybenzoic acid with 4-cyanobenzoic acid.
  • Example 205C 4-F(6-methoxy-l-oxo-5-f F2-(trimethylsilvPethoxylmethoxyl-2,3-dihvdro-lH-inden-2- vPcarbonyllbenzonitrile
  • Example 205A (5.4 g, 17.51 mmol) in 250 mL of THF was treated with NaH (60%, 1.06 g, 26.37 mmol). After the addition of Example 205B (5.2 g, 26.37 mmol), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. Yellow solid was collected, washed with water and dried. MS (DCI/NH3) m/z: 438.17 (M+H) + .
  • Example 205D 4-(7-methoxy-6- 1 F2-(trimethylsilyl)ethoxy1methoxy i - 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3- yPbenzonitrile
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 205C.
  • the title compound (6.5 g) was obtained at 88% yield.
  • Example 205E 4-(7-methoxy-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy)-l- ⁇ F2-(trimethylsilyl)ethoxylmethyl 1-1,4- dihydroindenoFl,2-clpyrazol-3-yl)benzonitrile
  • the desired product was prepared using the procedure in Example 175D replacing Example 175C with Example 205D.
  • the title compound (6.5 g) was obtained at 83% yield.
  • MS (DCI/NH3) m/z: 564.28 (M+H) + .
  • Example 205F 4-(6-h ydroxy-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 - vDbenzonitrile
  • Example 205E (50 mg, 0.089 mmol) in ethanol (2 mL) was treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours. The precipitate was collected by filtration to give the title compound (22 mg) at 82% yield.
  • 1H NMR 400 MHz, DMSO-Dg) ⁇ ppm 3.74 (s, 2 H) 3.84 (s, 3 H) 7.01 (s, 1 H) 7.20 (s, 1 H) 7.93 (s, 4 H).
  • Example 206A 4-(6-hydroxy-7-methoxy-l- ⁇ F2-(trimethylsilyl)ethoxy1methyll-l,4-dihvdroindenoFl,2-c1pyrazol-
  • Example 206B 4-F7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzonitrile
  • Example 206A 50 mg, 0.115 mmol
  • di-tert-butyl azodicarboxylate 53.1 mg, 0.23 mmol
  • polymer-supported PI1 3 P 3 mmol/g, 77 mg, 0.23 mmol
  • pyridin-2-yl-methanol 25.2 mg, 0.23 mmol
  • Example 220A 6-methoxy- 1 -oxo-2,3-dihydro- lH-inden-5-yl trifluoromethanesulfonate
  • Example 172A (6 g, 33.67 mmol), 2,6-lutidine (5.88 mL, 50.52 mmol), and 4- dimethylaminopyridine (822 mg, 6.72 mmol) were combined at -35°C - -30°C and then dropwise treated with triflic anhydride (8.52 mL, 50.64 mmol). The reaction mixture was slowly warmed to room temperature with stirring and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (9.8 g) was obtained at 94% yield. MS (DCIZNH 3 ) m/z: 328.01(M+NH 4 ) + .
  • Example 220B methyl 6-methoxy-l-oxomdane-5-carboxylate
  • Example 220A (5.7 g, 18.37 mmol), PdCl 2 (dppi CH 2 Cl 2 (1.5 g) and triethylamine (7.7 mL) were combined in methanol (50 mL) and stirred for 16 hours at 110°C under carbon monoxide atmosphere (500 psi). The solvent was removed, and the residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (3.1 g) was obtained at 77% yield. MS (DCI/NH3) m/z: 221.02(M+H) + .
  • Example 220C methyl 2-(4-cyanobenzoyl)-6-methoxy- 1 -oxoindane-5-carboxylate
  • Example 220D methyl 3-(4-cyanophenyl)-7-methoxy-l,4-dihvdroindenoFl,2-c1pyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 220C.
  • the title compound (3.7 g) was obtained at 81% yield.
  • Example 220E 3-(4-cyanophenyl)-7-methoxy- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazole-6-carboxylic acid
  • Example 220D (1 g, 2.90 mmol), 2 N NaOH (10 mL), THF(20 mL) and ethanol (20 mL) were combined and stirred overnight. The reaction mixture was concentrated, diluted with water and acidified with HCl. The precipitate was collected by filtration to give the title product (905 mg) at 85% yield. MS (DCI/NH 3 ) m/z: 349.06 (M+NH 4 ) + .
  • 1H NMR 500 MHz, DMSO-D 6 ) ⁇ ppm 3.89 (s, 2 H) 3.92 (s, 3 H) 7.39 (s, 1 H) 7.85 (s, 1 H) 7.98 (s, 4 H).
  • Example 220F 3-(4-cvanophenyl)-N-(4-hvdroxycvclohexyl)-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazole-6- carboxamide
  • Example 220E 50 mg, 0.15 mmol
  • 4-aminocyclohexanol 52 mg, 0.45 mmol
  • BOP Reagent 100 mg, 0.23 mmol
  • triethylamine 0.063 mL
  • Examples 221 to 227 represented by Figure (XII) and shown in Table 12 were synthesized in a similar fashion as described in Example 220F, except substituting the appropriate amine for 4-aminocyclohexanol.
  • Example 228A (trans) 4-1 F(3-iodo-7-methoxy-l,4-dihvdroindenoFl,2-clpyrazol-6- yPmethyll amino I c vclohexanol
  • Example 104E (150 mg, 0.44 mmol), trans-4-aminocyclohexanol hydrochloride (100 mg, 0.66 mmol) and K2CO 3 (91 mg, 0.66 mmol) were combined in ethanol (20 mL) and heated at 100°C for 3 hours and cooled. After addition of NaBH 4 (16.6 mg, 0.44 mmol), the reaction was stirred at room temperature overnight and concentrated.
  • Example 228 A (40 mg, 0.091 mmol), 4-cyanophenylboronic acid (16 mg, 0.11 mmol), Na 2 C0 3 (1 M, 0.25 mL), and Pd(PPh 3 ) 2 Cl 2 (6.4mg, 0.009mmol) were combined in DME/EtOH/H 2 O (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC. The title compound (20 mg) was obtained at 36% yield (based on 2TFA salt).
  • Example 229 A methyl 3 -(4-cyanophenvP-7-methoxy- 1-1 F2-(trimethylsilyl)ethoxy]methyl I - 1 ,4- dihvdroindeno F 1 ,2-clpyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 175D replacing Example 175C with Example 220D.
  • the title compound (1.5 g) was obtained at 91% yield.
  • Example 229B 4-(6-(hydroxymethyl)-7-methoxy- 1 - ⁇ F2-(trimethylsilyPethoxy1methyl ⁇ - 1 ,4-dihvdroindeno F 1 ,2- c1pyrazol-3-yl)benzonitrile
  • Example 229A 200 mg, 0.42 mmol
  • NaBH 160 mg, 4.2 mmol
  • the residue was purified by flash chromatography eluting with a mixture of ethyl acetate and hexane.
  • Example 229C 4- r6-( lH-imidazol- 1 -ylmethyl)-7-methoxy- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-yllbenzonitrile
  • Example 229B (20 mg, 0.045 mmol) and l,l'-carbonyldiimidazole (30 mg, 0.18 mmol) were combined in acetonitrate (3 mL), heated at 80°C for 24 hours and concentrated. The residue was treated with ethanol (2 mL) and 4 N HCl in dioxane (2 mL), and the reaction mixture was stirred overnight.
  • Example 230A 2-chloro-5-( lH-imidazol- 1 -ylcarbonvPpyridine
  • the desired product was prepared using the procedure in Example 165 A replacing 4- benzyloxybenzoic acid with 6-chloronicotinic acid.
  • Example 230B 2-F(6-chloropyridin-3-yl)earbonyll-5,6-dimethoxyindan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165A with Example 230A. MS (DCI/NH 3 ) m/z: 331.98 (M+H) + .
  • Example 230C 3-(6-chloropyridin-3-vP-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 230B.
  • the title product (937 mg) was obtained at 95% yield.
  • Example 166A with Example 230C MS (DCI/NH3) m/z: 386.09 (M+H) + .
  • Example 232 4-F5-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)pyridin-2-yll-2-methoxyphenol
  • the title product was prepared using the procedure in Example 164 replacing Example 64C with Example 230C at 83% yield.
  • Example 233 4-F5-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridin-2-yll-2-fluorophenol
  • the title product was prepared using the similar procedure in Example 232 replacing 2- methoxy-4-(4,4,5,5-tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol with 2-fluoro-4-(4,4,5,5- tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol.
  • Example 234 5-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-vPpyridine-2-carbonitrile The title product was prepared using the procedure in Example 167 replacing Example 64C with Example 230C. MS (DCI/MH 3 ) m z: 319.06 (M+H) + .
  • Example 235 6-(6,7-dimethoxy-l,4-dihvdiOindenoFl,2-clpyrazol-3-vPnicotinonitrile
  • Example 235A methyl 5-bromopyridine-2-carboxylate 2,5-Dibromopyridine (9.5 g, 40.10mmol), PdCl 2 (PPh 3 ) 2 (844 mg), triethylamine (8.36 mL), methanol (38 mL), and acetonitrile (114 mL) were combined, heated under carbon monoxide atmosphere (75 psi) at 60°C for 16 hours and concentrated.
  • Example 235B 2-F(5-bromopyridin-2-yl)carbonyn-5,6-dimethoxyindan-l-one
  • the desired product was prepared using the procedure in Example 165B replacing Example 165A with Example 235A.
  • the title compound (1.65 g) was obtained at 95% yield.
  • Example 235 C 3-(5-bromopyridin-2-yl)-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 235B.
  • the title compound (1.35 g) was obtained at 85% yield.
  • Example 235D 6-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)nicotinonitriIe
  • the title product was prepared using the procedure in Example 167 replacing Example 64C with Example 235C at 70% yield.
  • MS (DCI/MH3) m/z: 319.06 (M+H) + .
  • Example 236 4 '- F6-( 1 -hydroxy- 1 -methylethvP- 1 ,4-dihydroindeno Fl ,2-c1pyrazol-3-yll- 1 , 1 -biphenyl-4-ol
  • Example 236A methyl l,4-dihydroindenoFl,2-clpyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 220B replacing Example 220A with 6-bromo- l,4-dihydro-indeno[l,2-c]pyrazole (for preparation, see U.S. Patent 6297238).
  • Example 236B methyl 3-iodo- 1 ,4-dihydroindeno F 1 ,2-c1pyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 68B replacing Example 68A with 236A.
  • Example 236C 2-(3 -iodo- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-yl)propan-2-ol
  • THF 145 mL
  • 1.4 M MeMgBr 1.4 M MeMgBr in THF-toluene
  • the reaction mixture was slowly warmed to room temperature, stirred for 24 hours, quenched with aqueous NH4CI, and extracted with ethyl acetate. The organic layer was dried over MgS0 4 and concentrated.
  • Example 236D 4-F6-(l-hvdroxy-l-methylethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yll-l, -biphenyl-4-ol
  • Example 236C 45 mg, 0.13 mmol
  • Example 68D 47mg, 0.16 mmol
  • Na 2 CO 3 (1 M, 0.3 mL
  • Pd(PPh 3 ) 2 Cl 2 (9.9 mg, 0.014mmol) were combined in DME/EtOH/H 2 O (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer.
  • Example 237 4-F6-f 1 -hydroxy- 1 -methylethvP- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-ynbenzonitrile
  • the desired product was prepared using the procedure in Example 236D replacing Example 68D with 4-cyanophenyl boronic acid.
  • the title compound (27.8 g) was obtained at 51% yield.
  • Example 238A methyl l-oxoindane-5-carboxylate
  • the desired product was prepared using the procedure in Example 220B replacing Example 220A with 5-bromoindanone.
  • the title product was obtained at 85% yield.
  • Example 238B methyl 2-r(6-chloropyridm-3-yl)carbonyll-l-oxoindane-5-carboxylate
  • Example 238A (2.7 g, 14.2 mmol) in 45 mL of THF was treated with NaH (60%, 1.14 g, 28.4 mmol).
  • Example 230A (7.4 g, 35.5 mmol)
  • the reaction mixture was stirred overnight and poured into ice water.
  • the resulting mixture was acidified with concentrated HCl. Yellow solid was collected by filtration, washed with water and hot ethanol.
  • the title product (4.3 g) was obtained at 92% yield.
  • Example 238C methyl 3-(6-chloropyridin-3-yl)- 1 ,4-dihvdroindenoF 1 ,2-clpyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 238B.
  • the title compound (600 mg) was obtained at 74% yield.
  • Example 238D 2-F3-(6-chloropyridin-3-yl)-l,4-dihvdroindenoFl,2-c1pyrazol-6-yllpropan-2-ol
  • the desired product was prepared using the procedure in Example 236C replacing Example 236B with Example 238C.
  • the title compound (250 mg) was obtained at 83% yield.
  • Example 239 4- ⁇ 5-F6-(l-hvdroxy-l-methylethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridin-2-yl ⁇ phenol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 238D.
  • the title compound (25.1 mg) was obtained at 28% yield.
  • Example 240A 2,3-dichloro-5-(lH-imidazol-l-ylcarbonvPpyridine
  • the desired product was prepared using the procedure in Example 165 A replacing 4- benzyloxybenzoic acid with 5, 6-chloronicotinic acid.
  • Example 240B 2-F(5,6-dichloropyridin-3-yl)carbonyll-5,6-dimethoxyindan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165 A with Example 240A.
  • Example 165B with Example 240B MS (DCI/NH 3 ) m/z: 361.98 (M+H) + .
  • Example 241 2-F3-(6-fluoropyridm-3-yl)-l,4-dihydroindenoFl,2-clpyrazol-6-yllpropan-2-ol
  • the desired product was prepared using the procedure in Example 236D replacing Example 68D with 6-fluoronicotinic boronic acid.
  • the title compound (350 g) was obtained at 96% yield.
  • Example 242A 5,6-dimethoxy-2-(pyrazin-2-ylcarbonyl)indan-l-one
  • the desired product was prepared using the procedure in Example 165B replacing Example 165A with methyl pyrazine-2-carboxylate.
  • Example 165B with Example 242A MS (DCI/NH 3 ) m/z: 295.05 (M+H) + . ! H NMR (500 MHz,
  • Example 243A 6,7-dimethoxy- 1 ,4-dihvdroindeno Fl ,2-clpyrazole
  • 5 6-dimethoxyindanone
  • formic acid ethyl ester 5.04 mL, 62 mmol
  • 95% NaH 2.35 g, 93 mmol
  • benzene 100 mL
  • the solvent was removed.
  • To the residue was added slowly ethanol (200 mL), acetic acid (20 mL) and hydrazine monohydrate (20 mL). The mixture was heated to reflux for 3 hours and cooled. The solvents were removed.
  • Example 243B 3-iodo-6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazole
  • Example 243 A (5.80 g, 26.8 mmol), N-iodosuccinimide (7.84 g, 34.9 mmol), and anhydrous DMF (100 mL) were mixed, stirred at 80°C for 4 hours and concentrated. The residue was dissolved in dichloromethane (200 mL), washed with water (200 mLx3), dried over MgSO 4 and concentrated. The residue was purified by flash chromatography to give the title product as brown solid (5.84 g, 64%). MS (ESI) m/z 343 (M+H) + . ! H NMR (300 MHz, DMSO-Dg) ⁇ ppm 3.42 (s, 2 H) 3.79 (s, 3 H) 3.81 (s, 3 H) 7.15 (s, 1 H) 7.19 (s, 1 H)
  • Example 243C 6,7-dimethoxy-3-pyridin-3-yl-l,4-dihydroindenoFl,2-clpyrazole
  • Example 243B 100 mg, 0.29 mmol
  • pyridyl-3-boronic acid 43 mg, 0.35 mmol
  • Pd(PPh 3 ) 2 Cl 2 20 mg, 0.014mmol
  • Example 245A 6-methoxy-3-oxo-2,3-dihydro-lH-inden-5-yl trifluoromethanesulfonate
  • Example 144B (3.5 g, 19.64 mmol) and NaH (60%, 496 mg, 19.64 mmol) were combined and stirred at 40°C until no bubble came out from the reaction mixture.
  • N-phenyltrifluoromethanesulfonimide 8.41 g, 23.57 mmol
  • the reaction mixture was further stirred at 40°C for 30 min and concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title compound (5.5 g) was obtained at 90% yield.
  • Example 245B 5-methoxy-6-vinylindan- 1 -one
  • Example 245A (4.5 g, 14.5 mmol), tributylvinyltin (5.54 g, 17.4 mmol), Pd(PPh 3 ) 2 Cl 2 (1.02 g, 1.45 mmol) and lithium chloride (4.9 g, 116 mmol), were combined in DMF (60 mL) and heated at 80°C for 2 hours, cooled.
  • Example 245 C 6-ethyl-5 -methoxyindan- 1 -one
  • Example 245B (1.59 g, 8.46 mmol) and Pd-C (10%, 159 mg) were combined in THF (70 mL) and stirred under hydrogen atmosphere for 6 hours. Insoluble material was removed by filtration through Celite, the filtrate was evaporated to give the title product at quantitative yield.
  • Example 245D 2-F(6-chloropyridin-3-ypcarbonyll-6-ethyl-5-methoxymdan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 245C. The title compound (325 mg) was obtained at 71% yield.
  • Example 165B with Example 245D MS (DCI/NH 3 ) m/z: 326.04 (M+H) + .
  • Example 246 5-(7-ethyl-6-methoxy- 1 ,4-dihydroindenoFl ,2-c1pyrazol-3-yl)pyridine-2-carbonitrile
  • the title product was prepared using the procedure in Example 167 replacing Example 64C with Example 245E at 65% yield.
  • Example 245C (1 g, 5.31 mmol) in dichloromethane (25 mL) at -78°C was treated with BB1- 3 (2 mL, 21.24 mmol). The reaction mixture was warmed to room temperature and stirred for 24 hours. The reaction was quenched with water and extracted with ethyl acetate. Organic layer was dried over MgSO 4 and concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title compound (0.8 g) was obtained at 85% yield.
  • Example 247B 6-ethyl-5-(tetrahydro-2H-pyran-4-yloxy)indan- 1 -one
  • Example 247A 150 mg, 0.85mmol
  • polymer supported Ph 3 P 3 mmol/g, 0.57 g, 1.7 mmol
  • di-tert-butyl azodicarboxylate 392 mg, 1.70 mmol
  • tetrahydropyran-4-ol 174 mg, 1.70 mmol
  • Example 247C 2-F(6-chloropyridin-3-yl)carbonyn-6-ethyl-5-(tetrahvdro-2H-pyran-4-yloxy)indan-l-one
  • the desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 247B.
  • Example 247D 3-(6-chloropyridin-3-yl)-7-ethyl-6-(tetrahvdro-2H-pyran-4-yloxy)-1.4-dihydroindenoFl,2- clpyrazole
  • Example 248 4- ⁇ 5-F7-ethyl-6-(tetrahvdro-2H-pyran-4-yloxy)-l,4-dihydroindenoFl,2-clpyrazol-3-ynpyridin-2- yl ⁇ phenol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 247D.
  • the title compound (35.2 mg) was obtained at 43% yield.
  • Example 249A 6-ethyl-5 - ( F2-(trimethylsilyl)ethoxy1methoxy j indan- 1 -one
  • the desired product was prepared using the procedure in Example 205A replacing Example 172A with Example 247A.
  • Example 249B 2- F(6-chloropyridm-3-yl)carbonyll-6-ethyl-5- ⁇ F2-(trimethylsilyl)ethoxy1methoxy 1 indan- 1 -one
  • the desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 249A.
  • Example 249C 3-(6-chloropyridin-3-yl)-7-ethyl-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy I- 1 ,4-dihydroindeno Fl ,2- clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 249B.
  • the title compound (1.35 g) was obtained at 69% yield (for 3 steps).
  • Example 249D (900 mg, 1.57 mmol), Pd 2 (dba) 3 (36 mg, 0.039 mmol), dppf (43.5 mg, 0.078 mmol), zinc (204 mg, 0.39 mmol) and Zn(CN) 2 were combined in DMA (75 mL), heated at 130°C for 3 hours and concentrated.
  • Example 249F 5-( " 7-ethyl-6-hvdroxy-l- ⁇ F2-(trimethylsilyl)ethoxy1methyl
  • the desired product was prepared using the procedure in Example 206A replacing Example 205E with Example 249E.
  • the title compound (250 mg) was obtained at 81% yield.
  • Example 249G 5-F7-ethyl-6-(3-morpholin-4-ylpropoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2- carbonitrile
  • Example 249F (40 mg, 0.092mmol), polymer supported PI1 3 P (3 mmol/g, 46 mg, 0.139 mmol), di-tert-butyl azodicarboxylate (32 mg, 0.139 mmol) and 3-morpholin-4-ylpropan-l-ol (27 mg, 0.184 mmol) were combined in THF (3 mL) and stirred overnight. Insoluble material was removed by filtration, and the filtrate was concentrated.
  • Examples 250 to 254 represented by Figure (XIII) and shown in Table 13 were synthesized in a similar fashion as described in Example 249G, except substituting the appropriate alcohol for 3-morpholin-4-ylpropan-l-ol.
  • Example 255A 6-ethyl-l-oxo-2,3-dihydro-lH-inden-5-yl trifluoromethanesulfonate
  • the desired product was prepared using the procedure in Example 245 A replacing Example 144B with Example 247A.
  • the title compound (8.5 g) was obtained at 72% yield.
  • Example 255B 6-ethyl-5-vinylindan-l -one
  • the desired product was prepared using the procedure in Example 245B replacing Example 245A with Example 255A.
  • the title compound (430 mg) was obtained at 52% yield.
  • Example 255 C 2-F(6-chloropyridin-3-yPcarbonyll-6-ethyl-5-vinylindan-l-one
  • the desired product was prepared using the procedure in Example 238B replacing Example 238A with Example 255B.
  • the title compound was directly used for the preparation of Example 255D.
  • Example 255D 3-(6-chloropyridin-3-vP-7-ethyl-6-vinyl-l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 255C.
  • the title compound (250 mg) was obtained at 46% yield (for 2 steps).
  • Example 255E l-rbis(4-methoxyphenyl)methyll-3-(6-chloropyridin-3-yP-7-ethyl-6-vinyl-l,4- dihydroindenori ,2-clpyrazole
  • the desired product was prepared using the procedure in Example 170B replacing 4- iodo-lH-pyrazole with Example 255D.
  • the title product (220 mg) was obtained at 79% yield.
  • Example 255E (130 mg) and Pt/C (5%, 13 mg) were combined in THF and stirred for 4 hours under hydrogen atmosphere. The insoluble material was removed by filtration, and the filtrate was evaporated. The title compound was obtained at quantitative yield.
  • Example 256 3-(6-chloropyridm-3-yP-6,7-bis(2-methoxyethoxy -l,4-dihydiOindenoFl,2-c1pyrazole
  • Example 256 A 5 ,6-bis(2-methoxyethoxy)indan- 1 -one
  • Example 144A 800 mg, 4.88 mmol
  • 2-bromoethyl methyl ether 8 mL, 85.1 mmol
  • CS 2 CO 3 9 g, 27.6 mmol
  • Example 256B 2-F(6-chloropyridin-3-yPcarbonyll-5,6-bis(2-methoxyethoxy)indan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 256 A.
  • Example 256C 3-(6-chloropyridin-3-yl)-6,7-bis(2-methoxyethoxy -l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 256B.
  • the title compound (617 mg) was obtained at 82% yield (for 2 steps).
  • Example 257 5-F6,7-bis(2-methoxyethoxy)- 1 ,4-dihvdroindeno Fl ,2-clpyrazol-3-yllpyridine-2-carbonitrile
  • the title product was prepared using the procedure in Example 167 replacing Example 64C with Example 256C.
  • the title product was obtained at 85% yield.
  • MS (DC17NH 3 ) m/z: 424.16 (M+NH ) + .
  • Example 258A 6-hydroxy-7-methoxy-3-(4'- 1 F2-(trimethylsilvPethoxylmethoxy 1-1,1 -biphenyl-4-vD- 1 - ⁇ F2- (trimethylsilypethoxylmethyl I indeno F 1 ,2-clp yrazol-4( 1 H)-one
  • Example 175G 310 mg, 0.49 mmol
  • CS 2 CO 3 640 mg, 1.96 mmol
  • the residue was purified by flash chromatography eluting with 33% ethyl acetate in hexane. The title product (282 mg) was obtained at 89% yield.
  • MS (DCI/NH3) m/z: 645.29 (M+NH 4 ) + .
  • Example 258B 6-hydroxy-3-(4'-hydroxy-l, -biphenyl-4-yl)-7-methoxyindenoFl,2-c1pyrazol-4(lH)-one
  • Example 258A (30 mg, 0.46 mmol) in ethanol (2 mL) was treated with 4 N HCl in dioxane (2 mL). The reaction mixture was heated at 50°C overnight and concentarted. The residue was purified by preparative HPLC. The title compound (19 mg) was obtained at 85% yield. MS (DCI/NH 3 ) m/z: 385.09 (M+NH 4 ) + .
  • Examples 260 and 261 represented by Figure (XIV) and shown in Table 14 were synthesized in a similar fashion as described in Example 259, except substituting the appropriate alcohol for 2-piperidin-l-ylethanol.
  • Example 262A 4-(7-methoxy-4-oxo-6- ⁇ r2-(trimethylsilvPethoxylmethoxy ⁇ -l- ⁇ r2- (trimethylsilypethoxylmethyl 1-1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 -ypbenzonitrile
  • Example 205E (1.8 g, 3.19 mmol) and CS 2 CO3 (4.16 g, 12.76 mmol) were combined in DMF (50 mL) and heated under air at 50°C overnight. Inorganic salt was removed by filtration, and the filtrate was concentrated. The residue was purified by flash chromatography eluting with 25% ethyl acetate in hexane. The title product (1.82 g) was obtained at 99% yield. MS (DCI/NH 3 ) m/z: 578.25 (M+H) + .
  • Example 262B 4-(6-hydroxy-7-methoxy-4-oxo- 1 - ⁇ F2-(trimethylsilyl)ethoxy1methyl ⁇ - 1 ,4-dihvdroindeno F 1 ,2- c1pyrazol-3-yl)benzonitrile
  • the desired product was prepared using the procedure in Example 206A replacing Example 205E with Example 262A.
  • the title compound was obtained at quantitative yield.
  • Example 262C 4- ⁇ 6- F3 -(dimethylamino)propoxyl -7-methox v-4-oxo- 1 ,4-dihvdroindeno ⁇ 1 , 2-clpyrazol-3 - yllbenzonitrile
  • Example 262B (40 mg, 0.089 mmol), di-tert-butyl azodicarboxylate (42 mg, 0.18 mmol), polymer-supported PI13P (3 mmol/g, 60 mg, 0.18 mmol) and 3-dimethylaminopropanol (18.6 mg, 0.18 mmol) were combined in THF (3 mL).
  • Example 263 4-(6-hydroxy-7-methoxy-4-oxo-l,4-dihvdroindenoFl,2-clpyrazol-3-vPbenzonitrile The desired product was prepared using the procedure in Example 205F replacing
  • Examples 264 and 265 represented by Figure (XV) and shown in Table 15 were synthesized in a similar fashion as described in Example 262C, except substituting the appropriate alcohol for 3-dimethylaminopropanol.
  • Example 266A 3-(6-chloropyridin-3-yl)-6,7-dimethoxyindenori,2-c1pyrazol-4(lH)-one
  • Example 230C 300 mg, 0.91 mmol
  • CS 2 CO3 1.5 g, 4.6 mmol
  • the residue was suspended in water, and the orange solid were collected by filtration and dried.
  • the title product (287 mg) was obtained at 92% yield.
  • Example 266B 3-(6-chloro ⁇ yridin-3-yl)-6,7-dimethoxy-4-methyl- 1 ,4-dihydroindeno n ,2-clpyrazol-4-ol
  • THF 15 mL
  • GEbMgCl 1:1, 1.3 mL
  • the reaction was warmed to room temperature, stirred for 1 day, quenched with water and concentrated. The residue was purified by preparative HPLC. MS (DCI/NH 3 ) m/z: 358.03 (M+H) + .
  • Example 267A 1 -(4-bromobenzoyD- lH-imidazole
  • DMF 100 mL
  • l,l'-carbonyldiimidazole 39.42 g, 243.2 mmol
  • the reaction was completed and poured into ice water (1 L).
  • the precipitate was filtered, washed with water (2 L), and dried in vacuo to give the desired product (16.7 g, 68%).
  • Example 267B 6-(benzyloxy -5 -methoxyindan- 1 -one
  • Example 144B (8.65 g, 48.5 mmol), benzyl bromide (12 mL, 97.1 mmol), K 2 CO 3 (20.2 g, 146.2 mmol) and anhydrous acetone (500 mL) were mixed and refluxed overnight. Acetone was removed, and the concentrate was treated with water (300 mL). The precipitate was filtered, washed with water (300 mLx2), and dried to give the desired product (11.80 g, 91%).
  • Example 267C 6-(penzyloxy)-2-(4-bromobe ⁇ zoyl)-5-methoxyindan- 1 -one
  • a solution of Example 267B (11.50 g, 42.9 mmol) in anhydrous THF (200 mL) was added 95% NaH (3.25 g, 128.7 mmol). The mixture was stirred at room-temperature for 0.5 hour.
  • Example 267A (16.2 g, 64.35 mmol) in THF (50 mL) was added dropwise to the above mixture. The reaction was run overnight, and poured into water (1.5 L). Concentrated hydrochloric acid (30 mL) was added dropwise to neutralize the mixture.
  • Example 267D 7-(benzylo y)-3-(4-bromophenyl)-6-methoxy-l,4-dihydroindenori,2-clpyrazole
  • Example 267C 14.08 g, 31.2 mmol
  • hydrazine monohydrate (3.03 mL, 62.4 mmol)
  • absolute ethanol 300 mL
  • glacial acetic acid 3.57 mL, 62.4 mmol
  • the reaction was cooled.
  • the precipitate was filtered, washed with water (30 mLx2) and ethanol (30 mLx2), and dried in vacuo overnight to give the desired product (11.66 g, 84%).
  • MS (ESI) m/z 448 (M+H) +
  • Example 267E 7-(benzyloxy)-3-(4-bromophenyl)-6-methoxy- 1 - 1 r2-(trimethylsilyl)ethoxylmethyl I - 1 ,4- dihvdroindeno F 1 ,2-clpyrazole
  • 95% NaH 0.69 g, 27.41 mmol
  • 2-(trimethylsilyl)ethoxymethyl chloride 4.85 mL, 27.41 mmol
  • Example 267F 4'-(7-(benzyloxy)-6-methoxy- 1 - ( F2-(trimethylsilyl)ethoxylmethyl 1-1 ,4-dihydroindeno 1 ,2- clpyrazol-3-yP- 1 , 1 '-biphenyl-4-ol
  • Example 267E (518 mg, 0.896mmol), dichlorobis(triphenylphosphine)palladium(II) (63 m g, 0.090 mmol), 4-(hydroxyphenyl)boronic acid (147.3 mg, 1.07 mmol), IM Na 2 CO 3 solution (1 mL), DME/EtOH/H 2 0 (7:2:3, 3 mL) and a stirrerbar were mixed together in a capped tube.
  • DMF dimethyl methoxyl
  • To the solution of Example 267F (4.66 g, 7.9 mmol) in DMF (200 mL) was added 95 % NaH
  • Example 285 3 -(4 -hydroxy- 1 , 1 -biphenyl-4-yl)-6-methoxy- 1 ,4-dihydroindeno r 1 ,2-clpyrazol-7-ol
  • ethanol 2 mL
  • hydrochloric acid 2 mL
  • Example 267H To the solution of Example 267H (1.29 g, 2.04 mmol) in THF (10 mL) at room temperature was added 95% NaH (51.6 mg, 2.04 mmol). The mixture was stirred for half an hour, and N-phenyltrifluoromethane sulphonamide (0.88 g, 2.45 mmol) was added. The reaction mixture was stirred at 40°C overnight. The reaction mixture was purified by flash chromatography to give the desired product (1.80 g, 100%).
  • Example 286B 3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-F2-(4-methylpiperazin- 1 -yl)ethyll- 1 ,4- dihydroindenoF 1 ,2-clpyrazole-7-carboxamide
  • Example 286A (40 mg, 0.0524 mmol), 2-(4-methylpiperazin-l-yl)ethylamine (75 mg, 0.524 mmol), triethylamine (143 ⁇ L, 1.048 mmol), PdCl 2 (dppf) (10 mg, 0.00132 mmol), and dichloromethane (5 mL) were mixed under CO (100 psi) at 100°C for 5 days.
  • Examples 287 to 299 represented by Figure (XVII) and shown in Table 17 were synthesized in a similar fashion as described in Example 286B using the appropriate amine instead of 2-(4-methylpiperazin- 1 -yl)ethylamine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) utilisés pour inhiber des protéines kinases. La présente invention concerne également des procédés pour produire ces composés, des compositions contenant ces composés, ainsi que des procédés de traitement utilisant ces composés.
PCT/US2004/006921 2003-03-07 2004-03-04 Inhibiteurs de pyrazole kinase fusionnee tricyclique et tetracyclique WO2004080973A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04717503A EP1603885A1 (fr) 2003-03-07 2004-03-04 Inhibiteurs de pyrazole kinase fusionnee tricyclique et tetracyclique
MXPA05009576A MXPA05009576A (es) 2003-03-07 2004-03-04 Inhibidores de pirazol-quinasa triciclicos y tetraciclicos, fundidos.
JP2006509216A JP2006520400A (ja) 2003-03-07 2004-03-04 縮合三および四環式ピラゾールキナーゼ阻害剤
CA002517885A CA2517885A1 (fr) 2003-03-07 2004-03-04 Inhibiteurs de pyrazole kinase fusionnee tricyclique et tetracyclique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38432503A 2003-03-07 2003-03-07
US10/384,325 2003-03-07
US10/792,564 US7320986B2 (en) 2003-03-07 2004-03-03 Fused tri and tetra-cyclic pyrazole kinase inhibitors
US10/792,564 2004-03-03

Publications (1)

Publication Number Publication Date
WO2004080973A1 true WO2004080973A1 (fr) 2004-09-23

Family

ID=32993814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006921 WO2004080973A1 (fr) 2003-03-07 2004-03-04 Inhibiteurs de pyrazole kinase fusionnee tricyclique et tetracyclique

Country Status (5)

Country Link
EP (1) EP1603885A1 (fr)
JP (1) JP2006520400A (fr)
CA (1) CA2517885A1 (fr)
MX (1) MXPA05009576A (fr)
WO (1) WO2004080973A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118543A1 (fr) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Inhibiteur des kinases et utilisation de cet inhibiteur
CN102584830A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 二氢化茚酰胺化合物、其药物组合物及其用途
WO2014039831A1 (fr) * 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited Dihydropyrazolo[4,3-b]indoles substituées dans les positions 1 et 4
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
WO2016113261A1 (fr) * 2015-01-13 2016-07-21 Basf Se Composés tricycliques fusionnés, compositions comprenant ces composés et leur utilisation aux fins de lutte contre les invertébrés nuisibles
WO2024015425A1 (fr) 2022-07-14 2024-01-18 Fmc Corporation Benzoxazines herbicides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9497970B2 (en) * 2013-07-15 2016-11-22 Basf Se Pesticide compounds

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969373A (en) * 1959-10-27 1961-01-24 Smith Kline French Lab Trifluoromethylpyrazoloindenone derivatives
US2969371A (en) * 1959-02-03 1961-01-24 Robert A Braun Substituted indeno [1, 2-c] pyrazole derivatives
US3004983A (en) * 1960-05-16 1961-10-17 Smith Kline French Lab 4-aminopyrazolo [3, 4-a] indene derivatives
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3932430A (en) * 1971-10-13 1976-01-13 Sandoz, Inc. Substituted indeno, naphtho and cyclohepta pyrazoles
JPS60130521A (ja) * 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
WO1999017770A1 (fr) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Derives d'indeno[1,2-c]pyrazole utiles pour inhiber l'activite de tyrosine kinase
WO1999017769A1 (fr) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Derives d'indeno(1,2-c)-, de naphto(1,2-c)-, et de benzo(6,7)cyclohepta(1,2-c)pyrazole
WO2000027822A2 (fr) * 1998-11-06 2000-05-18 Basf Aktiengesellschaft Derives de pyrazole tricyclique
WO2000059901A1 (fr) * 1999-04-06 2000-10-12 Knoll Gesellschaft Mit Beschraenkter Haftung 1,4 dihydroindeno[1, 2-c]pyrazoles substitues utilises comme inhibiteurs de la tyrosine kinase
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
WO2001087846A2 (fr) * 2000-05-17 2001-11-22 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft Derives de pyrazole tricyclique
US20020183334A1 (en) * 2000-05-16 2002-12-05 Bacon Edward R. Substituted thioacetamides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD100256A5 (fr) * 1971-10-13 1973-09-12

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969371A (en) * 1959-02-03 1961-01-24 Robert A Braun Substituted indeno [1, 2-c] pyrazole derivatives
US2969373A (en) * 1959-10-27 1961-01-24 Smith Kline French Lab Trifluoromethylpyrazoloindenone derivatives
US3004983A (en) * 1960-05-16 1961-10-17 Smith Kline French Lab 4-aminopyrazolo [3, 4-a] indene derivatives
US3932430A (en) * 1971-10-13 1976-01-13 Sandoz, Inc. Substituted indeno, naphtho and cyclohepta pyrazoles
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
JPS60130521A (ja) * 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
WO1999017770A1 (fr) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Derives d'indeno[1,2-c]pyrazole utiles pour inhiber l'activite de tyrosine kinase
WO1999017769A1 (fr) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Derives d'indeno(1,2-c)-, de naphto(1,2-c)-, et de benzo(6,7)cyclohepta(1,2-c)pyrazole
WO2000027822A2 (fr) * 1998-11-06 2000-05-18 Basf Aktiengesellschaft Derives de pyrazole tricyclique
WO2000059901A1 (fr) * 1999-04-06 2000-10-12 Knoll Gesellschaft Mit Beschraenkter Haftung 1,4 dihydroindeno[1, 2-c]pyrazoles substitues utilises comme inhibiteurs de la tyrosine kinase
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US20020183334A1 (en) * 2000-05-16 2002-12-05 Bacon Edward R. Substituted thioacetamides
WO2001087846A2 (fr) * 2000-05-17 2001-11-22 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft Derives de pyrazole tricyclique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAUN, ROBERT A. ET AL: "1,3-Disubstituted indeno [1,2-c] pyrazol-4-ones", JOURNAL OF ORGANIC CHEMISTRY, CODEN: JOCEAH; ISSN: 0022-3263, vol. 24, 1959, pages 648 - 650, XP002288087 *
BRAUN, ROBERT A. ET AL: "Wolff-Kishner reduction of 2-acyl-1,3-indandiones", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , CODEN: JACSAT; ISSN: 0002-7863, vol. 80, 1958, pages 4919 - 4921, XP002288088 *
PATENT ABSTRACTS OF JAPAN vol. 009, no. 287 (C - 314) 14 November 1985 (1985-11-14) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118543A1 (fr) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Inhibiteur des kinases et utilisation de cet inhibiteur
CN102584830A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 二氢化茚酰胺化合物、其药物组合物及其用途
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
WO2014039831A1 (fr) * 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited Dihydropyrazolo[4,3-b]indoles substituées dans les positions 1 et 4
US9475816B2 (en) 2012-09-07 2016-10-25 Takeda Pharmaceutical Company Limited Substituted-1,4-dihydropyrazolo[4,3-b]indoles
WO2016113261A1 (fr) * 2015-01-13 2016-07-21 Basf Se Composés tricycliques fusionnés, compositions comprenant ces composés et leur utilisation aux fins de lutte contre les invertébrés nuisibles
WO2024015425A1 (fr) 2022-07-14 2024-01-18 Fmc Corporation Benzoxazines herbicides

Also Published As

Publication number Publication date
EP1603885A1 (fr) 2005-12-14
CA2517885A1 (fr) 2004-09-23
MXPA05009576A (es) 2005-12-12
JP2006520400A (ja) 2006-09-07

Similar Documents

Publication Publication Date Title
CA2464333C (fr) Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
JP6480944B2 (ja) ブロモドメイン阻害剤としての二環式複素環誘導体
EP0418845B1 (fr) Dérivés de pyrazole, leur procédé de préparation et composition pharmaceutique les contenant
JP7446316B2 (ja) 置換ピロリジンアミドｉｉｉ
TW200918054A (en) New heterocyclic H3 antagonists
KR20180100697A (ko) Ror-감마의 조절제로서의 벤즈이미다졸 유도체
CA2498966A1 (fr) Nouveaux analogues du pyrazole a effet sur les recepteurs cannabinoides
CA2515790C (fr) Inhibiteurs de kinase heterocyclique
JP2010539180A (ja) ヒスタミン３拮抗薬としてのイソキノリニルおよびイソインドリニル誘導体
EP1836200A1 (fr) Benzisothiazole-1,1-dioxyde en tant qu'antagonistes du récepteur vanilloïde de sous-type 1 (vr1) et applications dudit composé
WO2015091939A1 (fr) Dérivés de pipéridine ayant une activité multimodale contre la douleur
US7320986B2 (en) Fused tri and tetra-cyclic pyrazole kinase inhibitors
WO2020254552A2 (fr) Amides de pyrrolidine substitués v
JP2010533725A (ja) ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物
WO2004080973A1 (fr) Inhibiteurs de pyrazole kinase fusionnee tricyclique et tetracyclique
CN108349935B (zh) 吡咯烷衍生物
EP3986885A1 (fr) Amides de pyrrolidine substitués iv
US20020183309A1 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
AU2016378154B2 (en) Phenylimidazole compound
WO2016014913A1 (fr) Modulateurs indazoles du récepteur orphelin lié au récepteur de l'acide rétinoïque et leurs utilisations
CN106604917B (zh) 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物
TW202435863A (zh) Cbl-b抑制劑
JP5929812B2 (ja) １，２，４−トリアゾロン誘導体を含有する医薬
AU2002353895A1 (en) Heteroindanes: a new class of potent cannabimimetic ligands
AU2004201292A1 (en) Novel pyrazole analogs acting on cannabinoid receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2517885

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006509216

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009576

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004717503

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004717503

Country of ref document: EP